<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>y94774e10vk.htm
<DESCRIPTION>MERCK & CO., INC.
<TEXT>
<HTML>
<HEAD>
<TITLE>MERCK & CO., INC.</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<P align="center"><FONT size="2"><B>As filed with the Securities and
Exchange Commission on March&nbsp;10, 2004</B><BR><BR>
</FONT>

<HR size="4" noshade color="#000000" style="margin-top: -5px">
<HR size="1" noshade color="#000000" style="margin-top: -10px">




<P align="center"><FONT size="4"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>
</FONT>

<DIV align="center"><FONT size="3">WASHINGTON, D. C. 20549
</FONT></DIV>
<DIV align="center"><HR align="center" size="1" width="20%" noshade></DIV>
<P align="center"><FONT size="5"><B>FORM 10-K</B>
</FONT>

<P align="left"><FONT size="2">(<B>MARK ONE</B>)
</FONT>

<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="95%">
<TR valign="bottom">
    <TD width="8%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="87%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><FONT size="3">[X]</FONT></TD>
    <TD><FONT size="3">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="3">
<B>Annual Report Pursuant to Section&nbsp;13 or 15(d)</B></FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="3">&nbsp;</FONT></TD>
    <TD><FONT size="3">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="3">
<B>of the Securities Exchange Act of 1934</B></FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="3">&nbsp;</FONT></TD>
    <TD><FONT size="3">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
For the Fiscal Year Ended December&nbsp;31, 2003</FONT></TD>
</TR>
</TABLE>
</CENTER>
<P align="center"><FONT size="2">or
</FONT>

<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="95%">
<TR valign="bottom">
    <TD width="8%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="87%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><FONT size="3">[&nbsp;&nbsp;]</FONT></TD>
    <TD><FONT size="3">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="3">
<B>Transition Report Pursuant to Section&nbsp;13 or 15(d)</B></FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="3">&nbsp;</FONT></TD>
    <TD><FONT size="3">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="3">
<B>of the Securities Exchange Act of 1934</B></FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="3">&nbsp;</FONT></TD>
    <TD><FONT size="3">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
For the transition period from <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>to <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD>
</TR>
</TABLE>
</CENTER>
<P align="center"><FONT size="2"><B>Commission File No.&nbsp;1-3305</B>
</FONT>

<DIV align="center"><HR align="center" size="1" width="20%" noshade></DIV>
<P align="center"><FONT size="6"><B>Merck &#038; Co., Inc.</B>
</FONT>

<DIV align="center"><FONT size="2">One Merck Drive<BR>
Whitehouse Station, N. J. 08889-0100<BR>
(908)&nbsp;423-1000
</FONT></DIV>
<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%">
<TR valign="bottom">
    <TD width="50%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><FONT size="2"><I>Incorporated in New Jersey</I></FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="center" valign="top"><FONT size="2">
<I>I.R.S. Employer<BR>
Identification No.&nbsp;22-1109110</I></FONT></TD>
</TR>
</TABLE>
</CENTER>
<P align="center"><FONT size="2"><B>Securities Registered pursuant to Section&nbsp;12(b) of the Act:</B>
</FONT>

<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%">
<TR valign="bottom">
    <TD width="50%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><FONT size="2">&nbsp;<BR><I>Title of Each Class</I></FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="center" valign="top"><FONT size="2">
<I>Name of Each Exchange<BR>
on which Registered</I></FONT></TD>
</TR>
<TR>
    <TD align="center" valign="top"><HR size="1" noshade width="45%"></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="center" valign="top"><FONT size="2">
<HR size="1" noshade width="83%"></FONT></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><FONT size="2">Common Stock<BR>
($0.01 par value)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="center" valign="top"><FONT size="2">
New York and Philadelphia Stock Exchanges&nbsp;</FONT></TD>
</TR>
</TABLE>
</CENTER>
<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Number of shares of Common Stock ($0.01 par value) outstanding as of
February&nbsp;27, 2004: 2,224,326,514.
</FONT>
<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Aggregate market value of Common Stock ($0.01 par value) held by
non-affiliates on June&nbsp;30, 2003 based on closing price on June&nbsp;30, 2003:
$135,610,000,000.
</FONT>
<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate by check mark whether the registrant (1)&nbsp;has filed all reports
required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12&nbsp;months (or for such shorter period that the
registrant was required to file such reports), and (2)&nbsp;has been subject to such
filing requirements for the past 90&nbsp;days. <B>Yes [X] No
[&nbsp;&nbsp;]</B>
</FONT>

<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate by check mark if disclosure of delinquent filers pursuant to Item
405 of Regulation&nbsp;S-K is not contained herein, and will not be contained, to
the best of registrant&#146;s knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form&nbsp;10-K or any
amendment to this Form&nbsp;10-K. <B>&#091;&nbsp;&nbsp;&#093;</B>
</FONT>

<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate by check mark whether the registrant is an accelerated filer (as
defined in Exchange Act Rule&nbsp;12b-2). <B>Yes [X] No
[&nbsp;&nbsp;]</B>
</FONT>

<P align="center"><FONT size="2"><B>Documents Incorporated by Reference:</B>
</FONT>

<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%">
<TR valign="bottom">
    <TD width="51%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="44%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><FONT size="2"><I>Document</I></FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="center" valign="top"><FONT size="2">
<I>Part of Form&nbsp;10-K</I></FONT></TD>
</TR>
<TR>
    <TD align="center" valign="top"><HR size="1" noshade width="80%"></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="center" valign="top"><FONT size="2">
<HR size="1" noshade width="45%"></FONT></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><FONT size="2">Annual Report to stockholders for the fiscal year<BR>
ended December&nbsp;31, 2003<BR>
Proxy Statement for the Annual Meeting of<BR>
Stockholders to be held April&nbsp;27, 2004</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="center" valign="top"><FONT size="2">
Parts I and II&nbsp;<BR><BR>Part
III</FONT></TD>
</TR>
</TABLE>
</CENTER>
<P>
<HR size="1" noshade color="#000000" style="margin-top: -2px">
<HR size="4" noshade color="#000000" style="margin-top: -10px">







<P align="center"><FONT size="2"></FONT>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<!-- TOC -->
<A name="toc"><DIV align="CENTER" style="page-break-before:always"><U><B>TABLE OF CONTENTS</B></U></DIV></A>

<P><CENTER>
<TABLE border="0" width="90%" cellpadding="0" cellspacing="0">
<TR>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="76%"></TD>
</TR>
<TR><TD colspan="9"><A HREF="#000">PART I</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#001">Item&nbsp;1. Business</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#002">Item&nbsp;2. Properties</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#003">Item&nbsp;3. Legal Proceedings</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#004">Item&nbsp;4. Submission of Matters to a Vote of Security Holders</A></TD></TR>
<TR><TD colspan="9"><A HREF="#005">PART II</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#006">Item&nbsp;5. Market for Registrant&#146;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#007">Item&nbsp;6. Selected Financial Data</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#008">Item&nbsp;7. Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#009">Item&nbsp;7A. Quantitative and Qualitative Disclosures About Market Risk</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#010">Item&nbsp;8. Financial Statements and Supplementary Data</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#011">Item&nbsp;9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#012">Item&nbsp;9A. Controls and Procedures</A></TD></TR>
<TR><TD colspan="9"><A HREF="#013">PART III</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#014">Item&nbsp;10. Directors and Executive Officers of the Registrant</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#015">Item&nbsp;11. Executive Compensation</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#016">Item&nbsp;12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#017">Item&nbsp;13. Certain Relationships and Related Transactions</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#018">Item&nbsp;14. Principal Accountant Fees and Services</A></TD></TR>
<TR><TD colspan="9"><A HREF="#019">PART IV</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#020">Item&nbsp;15. Exhibits, Financial Statement Schedules, and Reports on Form&nbsp;8-K</A></TD></TR>
<TR><TD colspan="9"><A HREF="#021">SIGNATURES</A></TD></TR>
<TR><TD colspan="9"><A HREF="y94774exv10w3.htm">DEFERRAL PROGRAM (AMENDED AND RESTATED 11/19/03)</A></TD></TR>
<TR><TD colspan="9"><A HREF="y94774exv10w13.htm">DEFERRED PAYMENT OF DIRECTORS' COMPENSATION PLAN</A></TD></TR>
<TR><TD colspan="9"><A HREF="y94774exv10w15.htm">OFFER LETTER</A></TD></TR>
<TR><TD colspan="9"><A HREF="y94774exv12.htm">COMPUTATION OF RATIOS OF EARNINGS TO FIXED CHARGES</A></TD></TR>
<TR><TD colspan="9"><A HREF="y94774exv13.htm">PAGES FROM THE 2003 ANNUAL REPORT TO STOCKHOLDERS</A></TD></TR>
<TR><TD colspan="9"><A HREF="y94774exv14.htm">CODE OF CONDUCT</A></TD></TR>
<TR><TD colspan="9"><A HREF="y94774exv21.htm">LIST OF SUBSIDIARIES</A></TD></TR>
<TR><TD colspan="9"><A HREF="y94774exv24w1.htm">POWER OF ATTORNEY</A></TD></TR>
<TR><TD colspan="9"><A HREF="y94774exv24w2.htm">CERTIFIED RESOLUTION OF BOARD OF DIRECTORS</A></TD></TR>
<TR><TD colspan="9"><A HREF="y94774exv31w1.htm">CERTIFICATION OF CEO</A></TD></TR>
<TR><TD colspan="9"><A HREF="y94774exv31w2.htm">CERTIFICATION OF CFO</A></TD></TR>
<TR><TD colspan="9"><A HREF="y94774exv32w1.htm">CERTIFICATION OF CEO</A></TD></TR>
<TR><TD colspan="9"><A HREF="y94774exv32w2.htm">CERTIFICATION OF CFO</A></TD></TR>
</TABLE>
</CENTER>
<!-- /TOC -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>




<!-- link1 "PART I" -->
<DIV align="left"><A NAME="000"></A></DIV>

<P align="center" style="font-size: 10pt"><B>PART I</B>


<!-- link2 "Item&nbsp;1. Business" -->
<DIV align="left"><A NAME="001"></A></DIV>

<P align="left" style="font-size: 10pt"><B>Item&nbsp;1. Business.</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Merck &#038; Co., Inc. (the &#147;Company&#148;) is a global research-driven
pharmaceutical products company that discovers, develops, manufactures and
markets a broad range of innovative products to improve human and animal
health, directly and through its joint ventures. The Company sells its
products primarily to drug wholesalers and retailers, hospitals, clinics,
government agencies and managed health care providers such as health
maintenance organizations and other institutions. The Company&#146;s professional
representatives communicate the effectiveness, safety and value of its products
to health care professionals in private practice, group practices and managed
care organizations.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In January&nbsp;2002, the Company announced plans to establish Medco Health
Solutions, Inc. (&#147;Medco Health&#148;) as a separate, publicly-traded company. On
August&nbsp;19, 2003, the spin-off of Medco Health was effected by way of a pro rata
dividend to Company stockholders of all the outstanding shares of common stock
of Medco Health. Based on a letter ruling the Company received from the U.S.
Internal Revenue Service, receipt of Medco Health shares in the distribution
was tax-free for U.S. federal income tax purposes, but any cash received in
lieu of fractional shares was taxable.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Product Sales</I></B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sales<SUP>1,2</SUP> by category of the Company&#146;s products were as follows:

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="80%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="55%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center"><B>($ in millions)</B><HR size="1" noshade></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>2003</B><HR size="1" noshade></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>2002</B><HR size="1" noshade></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>2001</B><HR size="1" noshade></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Atherosclerosis</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">5,077.9</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">5,552.1</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">5,433.3</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Hypertension/heart failure</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,421.6</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,477.8</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,584.3</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Anti-inflammatory/analgesics</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,677.3</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,587.2</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,391.1</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Osteoporosis</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,676.6</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,243.1</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,629.7</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Respiratory</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,009.4</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,489.8</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,260.3</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Vaccines/biologicals</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,056.1</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,028.3</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,022.5</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Anti-bacterial/anti-fungal</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,028.5</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">821.0</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">750.4</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Ophthalmologicals</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">675.1</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">621.5</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">644.5</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Urology</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">605.5</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">547.3</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">545.4</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Human immunodeficiency virus (&#147;HIV&#148;)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">290.6</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">294.3</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">380.8</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Other</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,967.3</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,783.4</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,556.7</TD>
    <TD>&nbsp;</TD>
</TR>

<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:20px; text-indent:-10px">Total</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">22,485.9</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">21,445.8</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">21,199.0</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="4" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="4" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="4" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>





<P align="left" style="font-size: 10pt"><SUP>1</SUP>Following the spin-off, the Company&#146;s prior period Consolidated
Statements of Income and Cash Flows and related discussions have been
restated to present the results of Medco Health separately as
discontinued operations. As a result of the spin-off, product sales now
reflect sales to Medco Health as third-party sales based upon the net
selling price from the Company to Medco Health. Prior year amounts have
been restated to conform to the current year presentation.

<P align="left" style="font-size: 10pt"><SUP>2</SUP>Presented net of rebates and discounts.



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company&#146;s products include therapeutic and preventive agents,
generally sold by prescription, for the treatment of human disorders. Among
these are atherosclerosis products, of which <I>Zocor </I>(simvastatin)&nbsp;is the
largest-selling; hypertension/heart failure products, the most significant of
which are <I>Cozaar </I>(losartan potassium), <I>Hyzaar </I>(losartan potassium and
hydrochlorothiazide), and <I>Vasotec </I>(enalapril maleate);
anti-inflammatory/analgesics, which include <I>Vioxx </I>(rofecoxib)&nbsp;and <I>Arcoxia</I>
(etoricoxib), agents that specifically inhibit the COX-2 enzyme, which is
responsible for pain and inflammation (&#147;coxibs&#148;); an osteoporosis product,
<I>Fosamax </I>(alendronate sodium), for treatment and prevention of osteoporosis; a
respiratory product, <I>Singulair </I>(montelukast sodium), a leukotriene receptor
antagonist for treatment of asthma and for relief of symptoms of seasonal
allergic rhinitis; vaccines/biologicals, of which <I>M-M-R </I>II (measles, mumps and
rubella virus vaccine live), <I>Varivax </I>(varicella virus vaccine live), a live
virus vaccine for the prevention of chickenpox, and <I>Recombivax HB </I>(hepatitis B
vaccine &#091;recombinant&#093;) are the largest-selling; anti-bacterial/anti-fungal
products, which includes <I>Primaxin </I>(imipenem and cilastatin sodium), as well as
newer products <I>Cancidas </I>(caspofungin acetate) and <I>Invanz </I>(ertapenem sodium);
ophthalmologicals, of which <I>Cosopt </I>(dorzolamide hydrochloride and timolol
maleate ophthalmic solution) and


<P align="center" style="font-size: 10pt">2
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="left" style="margin-left: 0%; text-indent: 0%; margin-right: 0%; font-size: 10pt"><I>Trusopt </I>(dorzolamide hydrochloride ophthalmic
solution) are the largest-selling; a urology product, <I>Proscar </I>(finasteride),
for treatment of symptomatic benign prostate enlargement; and HIV products,
which include <I>Crixivan </I>(indinavir sulfate) and <I>Stocrin </I>(efavirenz), for the
treatment of human immunodeficiency viral infection in adults.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other primarily includes <I>Maxalt </I>(rizatriptan benzoate), for the treatment
of acute migraine headaches in adults, <I>Propecia </I>(finasteride), for the
treatment of male pattern hair loss, and other non-promoted products and
pharmaceutical and animal health supply sales to the Company&#146;s joint ventures
and revenue from the Company&#146;s relationship with AstraZeneca LP, primarily
relating to sales of <I>Nexium </I>(esomeprazole magnesium) and <I>Prilosec </I>(omeprazole).


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In January&nbsp;2003, the U.S. Food and Drug Administration (&#147;FDA&#148;) approved
<I>Cancidas</I>, the Company&#146;s once-daily intravenous anti-fungal medicine for the
treatment of candidemia (bloodstream infection) and the following candida
infections: intra-abdominal abscesses, peritonitis (infections within the
lining of the abdominal cavity) and pleural space infections (infections within
the lining of the lung). Also in January&nbsp;2003, the Company announced that the
FDA approved <I>Singulair </I>for the relief of symptoms of seasonal allergic rhinitis
in adults and children as young as 2&nbsp;years of age.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In March&nbsp;2003, the FDA approved <I>Emend </I>(aprepitant), the first member in a
new class of medicines, to be used in combination with other anti-vomiting
medicines to help prevent the acute and delayed nausea and vomiting associated
with initial and repeat courses of highly emetogenic cancer chemotherapy,
including high-dose cisplatin. Also in March&nbsp;2003, the FDA approved <I>Cozaar </I>as
the first and only hypertension medicine indicated to reduce the risk of stroke
in patients with hypertension and left ventricular hypertrophy (&#147;LVH&#148;). The
new indication is based on the landmark Losartan Intervention for Endpoint
Reduction in Hypertension study (&#147;LIFE&#148;). The LIFE study, with <I>Cozaar</I>, marks
the first time an antihypertensive treatment regimen has demonstrated a
reduction in the risk of stroke versus another antihypertensive treatment
regimen in hypertensive patients with LVH. In the LIFE study, black patients
with hypertension and LVH had a lower risk of stroke on atenolol than on
<I>Cozaar</I>.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In April&nbsp;2003, the FDA approved changes to the prescribing information for
<I>Zocor </I>to include results from the landmark Heart Protection Study with <I>Zocor </I>40
mg, which is now recommended, along with diet, as the starting dose for <I>Zocor</I>
for people with coronary heart disease or diabetes. <I>Zocor </I>40 mg is the first
and only cholesterol-lowering medication proven to reduce the risk of heart
attack and stroke in people with heart disease or diabetes regardless of
cholesterol level.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Acquisitions
</I>&#151; On February&nbsp;23, 2004, the Company announced that it
had agreed to acquire Aton Pharma, Inc., a privately held
biotechnology company focusing on the development of novel treatments
for cancer and other serious diseases. (See also page&nbsp;10.)

<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In January&nbsp;2003, the Company, through its wholly owned
subsidiary, MSD (Japan) Co., Ltd., launched a tender offer to acquire, for an
estimated aggregate purchase price of $1.5&nbsp;billion, the remaining 49% of the
common shares of Banyu Pharmaceutical Co., Ltd. (&#147;Banyu&#148;) that it did not
already own. In October&nbsp;2003, the Company announced that at the close of the
final count of shares in its second tender offer for all remaining shares in
Banyu, the Company owned 99.4% of the outstanding shares of Banyu common stock.
Japan is the world&#146;s second largest pharmaceutical market.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In July&nbsp;2001, the Company acquired Rosetta Inpharmatics, Inc., a
publicly-held Washington based informational genomics company that designs and
develops unique technologies to efficiently analyze gene data to predict how
medical compounds will interact with different kinds of cells in the body.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Joint Ventures </I>&#151; In 1982, the Company entered into an agreement with Astra
AB (&#147;Astra&#148;) to develop and market Astra products in the United States. In
1994, the Company and Astra formed an equally owned joint venture that
developed and marketed most of Astra&#146;s new prescription medicines in the United
States including <I>Prilosec</I>, the first of a class of medications known as proton
pump inhibitors, which slows the production of acid from the cells of the
stomach lining.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In 1998, the Company and Astra restructured the joint venture whereby the
Company acquired Astra&#146;s interest in the joint venture, renamed KBI Inc.
(&#147;KBI&#148;), and contributed KBI&#146;s operating assets to a new U.S. limited
partnership named Astra Pharmaceuticals, L.P. (the &#147;Partnership&#148;), in which the
Company maintains a limited partner interest. The Partnership, renamed
AstraZeneca LP, became the exclusive distributor of the products for


<P align="center" style="font-size: 10pt">3
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="left" style="margin-left: 0%; text-indent: 0%; margin-right: 0%; font-size: 10pt">which KBI
retained rights. The Company earns certain Partnership returns as well as
ongoing revenue based on sales of current and future KBI products. The
Partnership returns include a priority return provided for in the Partnership
Agreement, variable returns based, in part, upon sales of certain former Astra
USA, Inc. products, and a preferential return representing the Company&#146;s share
of undistributed Partnership GAAP earnings. In conjunction with the 1998
restructuring, for a payment of $443.0&nbsp;million, Astra purchased an option to
buy the Company&#146;s interest in the KBI products, excluding the Company&#146;s
interest in the gastrointestinal medicines <I>Nexium </I>and <I>Prilosec</I>. The Company
also granted Astra an option (the &#147;Shares Option&#148;) to buy the Company&#146;s common
stock interest in KBI, at an exercise price based on the net present value of
estimated future net sales of <I>Nexium </I>and <I>Prilosec</I>.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In April&nbsp;1999, Astra merged with Zeneca Group Plc, forming AstraZeneca AB
(&#147;AstraZeneca&#148;). As a result of the merger, in exchange for the Company&#146;s
relinquishment of rights to future Astra products with no existing or pending
U.S. patents at the time of the merger, Astra paid $967.4&nbsp;million, which is
subject to a true-up calculation in 2008 that may require repayment of all or a
portion of this amount. The merger also triggers a partial redemption of the
Company&#146;s limited partner interest in 2008. Furthermore, as a result of the
merger, AstraZeneca&#146;s option to buy the Company&#146;s interest in the KBI products
is exercisable in 2010 and the Company has the right to require AstraZeneca to
purchase such interest in 2008. In addition, the Shares Option is exercisable
two years after Astra&#146;s purchase of the Company&#146;s interest in the KBI products.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In 1989, the Company formed a joint venture with Johnson &#038; Johnson to
develop, market and manufacture consumer health care products in the United
States. This 50% owned joint venture was expanded into Europe in 1993, and into
Canada in 1996. The European extension currently markets and sells
over-the-counter pharmaceutical products in France, Germany, Italy, Spain and
the United Kingdom. Significant joint venture products are <I>Pepcid AC</I>
(famotidine), an over-the-counter form of the Company&#146;s ulcer medication <I>Pepcid</I>
(famotidine), as well as <I>Pepcid Complete, </I>an over-the-counter product which
combines the Company&#146;s ulcer medication with antacids (calcium carbonate and
magnesium hydroxide). On February&nbsp;27, 2004, the Company announced its
intention to sell to Johnson &#038; Johnson its interest in the European joint
venture which is discussed on page 8 under <I>Divestitures</I>.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effective April&nbsp;1992, the Company, through the Merck Vaccine Division, and
Connaught Laboratories, Inc. (now Aventis Pasteur), agreed to collaborate on
the development and marketing of combination pediatric vaccines and to promote
selected vaccines in the United States. The research and marketing
collaboration enables the companies to pool their resources to expedite the
development of vaccines combining several different antigens to protect
children against a variety of diseases, including Haemophilus influenzae type
b, hepatitis B, diphtheria, tetanus, pertussis and poliomyelitis. While
combination vaccine development efforts continue under this Agreement, no
vaccines are currently being promoted.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In 1994, the Company, through the Merck Vaccine Division, and Pasteur
M&#233;rieux Connaught (now Aventis Pasteur) formed a joint venture to market human
vaccines in Europe and to collaborate in the development of combination
vaccines for distribution in the then existing European Union (&#147;EU&#148;) and the
European Free Trade Association. The Company and Aventis Pasteur contributed,
among other things, their European vaccine businesses for equal shares in the
joint venture, known as Pasteur M&#233;rieux MSD, S.N.C. (now Aventis Pasteur MSD,
S.N.C.). The joint venture is subject to monitoring by the EU, to which the
partners made certain undertakings in return for an exemption from European
Competition Law, effective until December&nbsp;2006. The joint venture maintains a
presence, directly or through affiliates or branches in Belgium, Italy,
Germany, Spain, France, Austria, Ireland, Sweden and the United Kingdom, and
through distributors in the rest of Europe.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In 1997, the Company and Rh&#244;ne-Poulenc S.A. combined their respective
animal health and poultry genetics businesses to form Merial Limited
(&#147;Merial&#148;), a fully-integrated animal health company, which is a stand-alone
joint venture, equally owned by each party. Merial provides a comprehensive
range of pharmaceuticals and vaccines to enhance the health, well-being and
performance of a wide range of animal species. In December&nbsp;1999, Rh&#244;ne-Poulenc
S.A.&#146;s interest in Merial was acquired by Aventis S.A., a corporation
formed by the merger of Rh&#244;ne-Poulenc S.A. and Hoechst A.G.


<P align="center" style="font-size: 10pt">4
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In 2000, the Company and Schering-Plough Corporation (&#147;Schering-Plough&#148;)
entered into agreements to create separate equally owned partnerships to
develop and market in the United States new prescription medicines in the
cholesterol-management and respiratory therapeutic areas. In December&nbsp;2001,
the Company and Schering-Plough announced the worldwide expansion (excluding
Japan) of the cholesterol-management partnership. In October&nbsp;2002,
Merck/Schering-Plough Pharmaceuticals (&#147;MSP&#148;) announced the FDA approval of
<I>Zetia </I>(ezetimibe). The once-daily tablet of <I>Zetia </I>10 mg was approved for use
either by itself or together with a statin to reduce LDL cholesterol and total
cholesterol in patients with high cholesterol. Marketing approval was received
in October&nbsp;2002 in Germany under the brand name <I>Ezetrol </I>for use alone and with
all marketed statins for the treatment of elevated cholesterol levels. In
2003, following the successful completion of the European Union Mutual
Recognition Procedure (&#147;MRP&#148;), <I>Ezetrol </I>had been launched in five European
countries &#150; Germany, the United Kingdom, Switzerland, Sweden and the
Netherlands. With the completion of the MRP process, the 15 EU member states,
as well as Iceland and Norway, can grant national marketing authorization with
unified labeling for <I>Ezetrol. </I>In the EU, <I>Ezetrol </I>will be indicated in
co-administration with a statin as adjunctive therapy to diet for use in
patients with primary hypercholesterolemia who are not appropriately controlled
with a statin alone. <I>Ezetrol </I>as monotherapy will be indicated as adjunctive
therapy to diet for use in patients with primary hypercholesterolemia in whom a
statin is considered inappropriate or is not tolerated. In addition, <I>Ezetrol</I>
as monotherapy will be indicated as adjunctive therapy to diet for use in
patients with homozygous familial sitosterolemia and co-administered with a
statin for use in patients with homozygous familial hypercholesterolemia. In
September&nbsp;2003, MSP submitted to the FDA for standard review a New Drug
Application (&#147;NDA&#148;) for <I>Vytorin</I>, an investigational cholesterol lowering
medicine, which contains the active ingredients of both <I>Zetia </I>and <I>Zocor</I>, as
adjunctive to diet, for the reduction of hypercholesterolemia (elevated
cholesterol levels). In November&nbsp;2003, the filing was accepted by the FDA for
standard review. Similar applications have been filed in other countries
outside the United States.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Competition </I>&#151; The markets in which the Company&#146;s pharmaceutical business
is conducted are highly competitive and often highly regulated. Global efforts
toward health care cost containment continue to exert pressure on product
pricing and access.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Such competition involves an intensive search for technological
innovations and the ability to market these innovations effectively. With its
long-standing emphasis on research and development, the Company is well
prepared to compete in the search for technological innovations. Additional
resources to meet competition include quality control, flexibility to meet
customer specifications, an efficient distribution system and a strong
technical information service. The Company is active in acquiring and
marketing products through joint ventures and licenses and has been refining
its sales and marketing efforts to further address changing industry
conditions. To enhance its product portfolio, the Company continues to pursue
external alliances, from early-stage to late-stage product opportunities,
including joint ventures and targeted acquisitions. However, the introduction
of new products and processes by competitors may result in price reductions and
product replacements, even for products protected by patents. For example, the
number of compounds available to treat diseases typically increases over time
and has resulted in slowing the growth in sales of certain of the Company&#146;s
products.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition, particularly in the area of human pharmaceutical products,
legislation enacted in all states in the U.S. allows, encourages or, in a few
instances, in the absence of specific instructions from the prescribing
physician, mandates the use of &#147;generic&#148; products (those containing the same
active chemical as an innovator&#146;s product) rather than &#147;brand-name&#148; products.
Governmental and other pressures toward the dispensing of generic products have
significantly reduced the sales of certain of the Company&#146;s products no longer
protected by patents, such as <I>Vasotec </I>and <I>Vaseretic </I>(enalapril maleate in
combination with hydrochlorothiazide)<I>, </I>the U.S. rights to which have been sold,
<I>Prinivil </I>(lisinopril) and <I>Prinzide </I>(lisinopril in combination with hydrochlorothiazide),
<I>Pepcid </I>and <I>Mevacor </I>(lovastatin), and slowed the growth of certain other
products.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Distribution </I>&#151; The Company sells its human health products primarily to
drug wholesalers and retailers, hospitals, clinics, government agencies and
managed health care providers such as health maintenance organizations and
other institutions. Vaccines are also sold directly to physicians. The
Company&#146;s professional representatives


<P align="center" style="font-size: 10pt">5
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="left" style="margin-left: 0%; text-indent: 0%; margin-right: 0%; font-size: 10pt">communicate the effectiveness, safety
and value of the Company&#146;s products to health care professionals in private
practice, group practices and managed care organizations.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the fourth quarter of 2003, the Company implemented a new distribution
program for U.S. wholesalers to moderate the fluctuations in sales caused by
wholesaler investment buying and improve efficiencies in the distribution of
Company pharmaceutical products. The new program has lowered previous limits
on average monthly purchases of Company pharmaceutical products by U.S.
customers. Overall, implementation of the new U.S. wholesaler distribution
program had an estimated $700.0 to $750.0&nbsp;million unfavorable impact on
consolidated revenues with an estimated $500.0&nbsp;million unfavorable effect on
<I>Zocor </I>sales.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Raw Materials </I>&#151; Raw materials and supplies are normally available in
quantities adequate to meet the needs of the Company&#146;s business.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Government Regulation and Investigation </I>&#151; The pharmaceutical industry is
subject to global regulation by regional, country, state and local agencies.
Of particular importance is the FDA in the United States, which administers
requirements covering the testing, approval, safety, effectiveness,
manufacturing, labeling and marketing of prescription pharmaceuticals. In many
cases, the FDA requirements have increased the amount of time and money
necessary to develop new products and bring them to market in the United
States. In 1997, the Food and Drug Administration Modernization Act was passed
and was the culmination of a comprehensive legislative reform effort designed
to streamline regulatory procedures within the FDA and to improve the
regulation of drugs, medical devices and food. The legislation was principally
designed to ensure the timely availability of safe and effective drugs and
biologics by expediting the premarket review process for new products. A key
provision of the legislation is the re-authorization of the Prescription Drug
User Fee Act of 1992, which permits the continued collection of user fees from
prescription drug manufacturers to augment FDA resources earmarked for the
review of human drug applications. This helps provide the resources necessary
to ensure the prompt approval of safe and effective new drugs.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the United States, the government made significant progress in
expanding health care access by enacting the Medicare Prescription Drug,
Improvement and Modernization Act of 2003, which was signed into law in
December&nbsp;2003. This statute adds prescription drug coverage to Medicare
beginning in 2006 and a voluntary drug discount card for Medicare beneficiaries
effective in June&nbsp;2004. Implementation of the new benefit will support the
Company&#146;s goal of improving access to medicines by expanding insurance
coverage, while preserving market-based incentives for pharmaceutical
innovation. At the same time, the benefit is designed to assure that
prescription drug costs will be controlled by competitive pressures and by
encouraging the appropriate use of medicines. The Company has taken a
leadership role in contributing to the success of the new Medicare-endorsed
discount cards by offering to provide its medicines free during 2004 and 2005
for low-income Medicare beneficiaries who exhaust their $600 transitional
assistance allowance in Medicare-endorsed drug discount cards. This action is
consistent with the Company&#146;s longstanding Patient Assistance Program, which
provides free medicines to patients in the United States who lack drug coverage
and cannot afford their medicines.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addressing cost containment outside of Medicare, the Company has made a
continuing effort to demonstrate that its medicines can help save costs in
overall patient health care. In addition, pricing flexibility across the
Company&#146;s product portfolio has encouraged growing use of its medicines and
mitigated the effects of increasing cost pressures.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For many years, the pharmaceutical industry has been under federal and
state oversight with the approval process for new drugs, drug safety,
advertising and promotion, drug purchasing and reimbursement programs and
formularies variously under review. The Company believes that it will continue
to be able to conduct its operations, including the introduction of new drugs
to the market, in this regulatory environment. One type of federal initiative
to contain federal health care spending is the prospective or &#147;capitated&#148;
payment system, first implemented to reduce the rate of growth in Medicare
reimbursement to hospitals. Such a system establishes in advance a flat rate
for reimbursement for health care for those patients for whom the payer is
fiscally responsible. This type of payment system and other cost containment
systems are now widely used by public and private payers and have caused
hospitals, health maintenance organizations and other customers of the Company
to be more cost-conscious in their


<P align="center" style="font-size: 10pt">6
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="left" style="margin-left: 0%; text-indent: 0%; margin-right: 0%; font-size: 10pt">treatment decisions, including decisions
regarding the medicines to be made available to their patients. The Company
continues to work with private and federal employers to slow increases in
health care costs. Further, the Company&#146;s efforts to demonstrate that its
medicines can help save costs in other areas, and pricing flexibility across
its product portfolio, have encouraged the use of the Company&#146;s medicines and
have helped offset the effects of increasing cost pressures.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Also, federal and state governments have pursued methods to directly
reduce the cost of drugs and vaccines for which they pay. For example, federal
laws require the Company to pay specified rebates for medicines reimbursed by
Medicaid, to provide discounts for outpatient medicines purchased by certain
Public Health Service entities and &#147;disproportionate share&#148; hospitals
(hospitals meeting certain criteria), and to provide minimum discounts of 24%
off of a defined &#147;non-federal average manufacturer price&#148; for purchases by
certain components of the federal government such as the Department of Veterans
Affairs and the Department of Defense.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Initiatives in some states seek rebates beyond the minimum required by
Medicaid legislation, in some cases for patients beyond those who are eligible
for Medicaid. Under the Federal Vaccines for Children entitlement program, the
U.S. Centers for Disease Control and Prevention (&#147;CDC&#148;) funds and purchases
recommended pediatric vaccines at a public sector price for the immunization of
Medicaid-eligible, uninsured, native American and certain underinsured
children. The Company was awarded CDC contracts in 2003 for the supply of
$345.7&nbsp;million of pediatric vaccines for this program (and a monovalent
component of certain of such vaccines).


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Outside the United States, the Company encounters similar regulatory and
legislative issues in most of the countries where it does business. There,
too, the primary thrust of governmental inquiry and action is toward
determining drug safety and effectiveness, often with mechanisms for
controlling the prices of prescription drugs and the profits of prescription
drug companies. The EU has adopted directives concerning the classification,
labeling, advertising, wholesale distribution and approval for marketing of
medicinal products for human use. The Company&#146;s policies and procedures are
already consistent with the substance of these directives; consequently, it is
believed that they will not have any material effect on the Company&#146;s business.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company is subject to the jurisdiction of various regulatory agencies
and is, therefore, subject to potential administrative actions. Such actions
may include seizures of products and other civil and criminal sanctions. Under
certain circumstances, the Company on its own may deem it advisable to initiate
product recalls. The Company believes that it should be able to compete
effectively within this environment.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition, certain countries within the EU, recognizing the economic
importance of the research-based pharmaceutical industry and the value of
innovative medicines to society, are working with industry representatives and
the European Commission on proposals to complete the &#147;Single Market&#148; in
pharmaceuticals and improve the competitive climate through a variety of means
including market deregulation.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There has been an increasing amount of focus on privacy issues in
countries around the world, including the United States and the EU. In the
United States, federal and state governments have pursued legislative and
regulatory initiatives regarding patient privacy, including federal and
recently issued state privacy regulations concerning health information, which
have affected the Company&#146;s operations.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Patents, Trademarks and Licenses </I>&#151; Patent protection is considered, in the
aggregate, to be of material importance in the Company&#146;s marketing of human
health products in the United States and in most major foreign markets.
Patents may cover products <I>per se</I>, pharmaceutical formulations, processes for
or intermediates useful in the manufacture of products or the uses of products.
Protection for individual products extends for varying periods in accordance
with the date of grant and the legal life of patents in the various countries.
The protection afforded, which may also vary from country to country, depends
upon the type of patent and its scope of coverage.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Patent portfolios developed for products introduced by the Company
normally provide market exclusivity. Basic patents are in effect for the
following major products in the United States: <I>Arcoxia, Cancidas, Comvax</I>
(haemophilus b conjugate and hepatitis B &#091;recombinant&#093; vaccine)<I>, Cosopt,
Cozaar, Crixivan</I>, <I>Emend, Fosamax,</I>


<P align="center" style="font-size: 10pt">7
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="left" style="margin-left: 0%; text-indent: 0%; margin-right: 0%; font-size: 10pt"><I>Hyzaar</I>, <I>Invanz, Maxalt, PedvaxHIB</I>
(haemophilus b conjugate vaccine)<I>, Primaxin, Propecia, Proscar, Recombivax HB,
Singulair, Timoptic-XE </I>(timolol maleate ophthalmic gel forming solution),
<I>Trusopt, Vioxx and Zocor</I>. A basic patent is also in effect in the United
States for <I>Zetia</I>, which was developed by the Merck/Schering-Plough
Pharmaceuticals partnership. A basic patent is also in effect for
<I>Sustiva/Stocrin </I>(efavirenz). Bristol-Myers Squibb, under an exclusive license
from the Company, sells <I>Sustiva </I>in the United States, Canada and certain
European countries. The Company markets <I>Stocrin </I>in other countries throughout
the world. The basic patent for <I>Aggrastat </I>(tirofiban hydrochloride) in the
United States was divested with the product in 2003. The Company retains basic
patents for <I>Aggrastat </I>outside the United States.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In 2003, <I>Zocor </I>lost its basic patent protection in Canada and certain
countries in Europe, including the United Kingdom and Germany, and the Company
experienced a decline in <I>Zocor </I>sales in those countries. In 2006, <I>Zocor </I>will
lose its market exclusivity in the United States and the Company expects a
decline in U.S. <I>Zocor</I> sales.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The FDA Modernization Act of 1997 (the &#147;Modernization Act&#148;), includes a
Pediatric Exclusivity Provision that may provide an additional six months of
market exclusivity in the United States for indications of new or currently
marketed drugs, if certain agreed upon pediatric studies are completed by the
applicant. These exclusivity provisions were re-authorized until October&nbsp;1,
2007 by the &#147;Best Pharmaceuticals for Children Act&#148; passed in January&nbsp;2002. In
2003, the FDA granted an additional six months of market exclusivity in the
United States to <I>Fosamax </I>until February&nbsp;2008, and <I>Fosamax </I>Once Weekly until
January&nbsp;2019. In addition, in 2004, the FDA granted an additional six months
of market exclusivity in the United States to <I>Trusopt </I>until October&nbsp;2008 and to
<I>Vioxx </I>for six months beyond its patent termination.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;While the expiration of a product patent normally results in a loss of
market exclusivity for the covered pharmaceutical product, commercial benefits
may continue to be derived from: (i)&nbsp;later-granted patents on processes and
intermediates related to the most economical method of manufacture of the
active ingredient of such product; (ii)&nbsp;patents relating to the use of such
product; (iii)&nbsp;patents relating to novel compositions and formulations; and
(iv)&nbsp;in the United States, market exclusivity that may be available under
federal law. The effect of product patent expiration on pharmaceutical
products also depends upon many other factors such as the nature of the market
and the position of the product in it, the growth of the market, the
complexities and economics of the process for manufacture of the active
ingredient of the product and the requirements of new drug provisions of the
Federal Food, Drug and Cosmetic Act or similar laws and regulations in other
countries.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additions to market exclusivity are sought in the United States and other
countries through all relevant laws, including laws increasing patent life.
Some of the benefits of increases in patent life have been partially offset by
a general increase in the number of, incentives for and use of generic
products. Additionally, improvements in intellectual property laws are sought
in the United States and other countries through reform of patent and other
relevant laws and implementation of international treaties.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Worldwide, all of the Company&#146;s important products are sold under
trademarks that are considered in the aggregate to be of material importance.
Trademark protection continues in some countries as long as used; in other
countries, as long as registered. Registration is for fixed terms and can be
renewed indefinitely.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Royalties received during 2003 on patent and know-how licenses and other
rights amounted to $86.5&nbsp;million. The Company also paid royalties amounting to
$757.7&nbsp;million in 2003 under patent and know-how licenses it holds.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Divestitures </I>&#151; On February&nbsp;27, 2004, the Company announced that it had
signed a definitive agreement with Johnson &#038; Johnson for Johnson &#038; Johnson to
buy the Company&#146;s 50&nbsp;percent equity stake in their European non-prescription
pharmaceuticals joint venture.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In 2003, the Company sold its U.S. rights in <I>Aggrastat </I>(tirofiban
hydrochloride injection) to Guilford Pharmaceuticals Inc. (&#147;Guilford&#148;),
including the basic U.S. product patents (but not process patents) for the
product.


<P align="center" style="font-size: 10pt">8
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In 2002, the Company sold its U.S. rights in <I>Vasotec, Vaseretic, </I>and
<I>Vasotec I.V. Injection </I>(enalaprilat)&nbsp;to Biovail Laboratories Incorporated
(&#147;Biovail&#148;), a subsidiary of Biovail Corporation. At the same time, the
Company&#146;s Canadian subsidiary, Merck Frosst Canada &#038; Co. (&#147;Merck Frosst&#148;) and
Biovail entered into a supply agreement under which Merck Frosst agreed to
supply Biovail for a minimum of five years with bulk tablets of formulated
enalapril maleate and enalapril maleate in combination with hydrochlorothiazide
for distribution by Biovail in the United States as <I>Vasotec </I>and <I>Vaseretic. </I>The
basic product patents on <I>Vasotec </I>and <I>Vaseretic </I>had expired in the United States
prior to these transactions.


<P align="left" style="font-size: 10pt"><B>Research and Development</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company&#146;s business is characterized by the introduction of new
products or new uses for existing products through a strong research and
development program. Approximately 12,800 people are employed in the Company&#146;s
research activities. Expenditures for the Company&#146;s research and development
programs were $3.2&nbsp;billion in 2003, $2.7&nbsp;billion in 2002 and $2.5&nbsp;billion in
2001 and are estimated to increase at a low-teen percentage growth rate over
the full-year 2003 expense in 2004. The Company maintains its ongoing
commitment to research over a broad range of therapeutic areas and clinical
development in support of new products. Total expenditures for the period 1994
through 2003 exceeded $20.2&nbsp;billion with a compound annual growth rate of 10%.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company maintains a number of long-term exploratory and fundamental
research programs in biology and chemistry as well as research programs
directed toward product development. Projects related to human health are
being carried on in various fields such as bacterial, fungal, and viral infections,
cardiovascular disease and atherosclerosis, cancer, diabetes,
obesity, neurodegenerative disease, psychiatric disease, pain and
inflammation, immunology, respiratory diseases, ophthalmology,
respiratory diseases, osteoporosis and men/women health programs, endoparasitic and ectoparasitic diseases,
companion animal diseases, and
production improvement.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the development of human health products, industry practice and
government regulations in the United States and most foreign countries provide
for the determination of effectiveness and safety of new chemical compounds
through preclinical tests and controlled clinical evaluation. Before a new
drug may be marketed in the United States, recorded data on preclinical and
clinical experience are included in the NDA or the biological Product License
Application (&#147;PLA&#148;) to the FDA for the required approval. The development of certain
other products is also subject to government regulations covering safety and
efficacy in the United States and many foreign countries. There can be no
assurance that a compound that is the result of any particular program will
obtain the regulatory approvals necessary for it to be marketed.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company&#146;s late-stage pipeline candidates include novel vaccines for
human papillomavirus (&#147;HPV&#148;) and the pain associated with shingles, and
<I>RotaTeq</I>, a vaccine for rotavirus-a highly contagious virus that is the most
common cause of severe gastroenteritis in infants and young children. The
Company expects to file PLAs with the FDA for
these three novel vaccine candidates in the second half of 2005. There are
competing claims to intellectual property in the HPV field, but the Company is
confident that the claims will not delay the Company&#146;s program. The Company
expects to submit a PLA to the FDA for its <I>ProQuad </I>vaccine, a pediatric
combination vaccine for measles, mumps, rubella and chickenpox, in the second
half of 2004.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company is also studying a DP-IV inhibitor, a glucose-lowering
mechanism, used alone and in combination for the treatment of Type II diabetes.
The Company plans to enter Phase III clinical trials with this investigational
compound in the second quarter of 2004 and expects to submit an NDA to the FDA
in 2006.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company&#146;s early-stage pipeline includes candidates in each of the
following areas: diabetes, obesity, Alzheimer&#146;s disease, respiratory disease,
coronary heart disease, rheumatoid arthritis and vaccines.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company supplements its internal research with an aggressive licensing
and external alliance strategy focused on the entire spectrum of collaborations
from early research to late-stage compounds, as well as new technologies. In
2003, the Company completed 47 significant transactions, including research
collaborations, preclinical and clinical compounds, and technology
transactions. Transactions completed in 2003 include agreements


<P align="center" style="font-size: 10pt">9
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="left" style="margin-left: 0%; text-indent: 0%; margin-right: 0%; font-size: 10pt">with the
following companies: GenPath, for cancer; Amrad, for respiratory disease;
Neurogen, for pain; and Actelion, for cardiovascular disease.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On February&nbsp;10, 2004, the Company announced that it had entered into an
agreement with H. Lundbeck A/S (&#147;Lundbeck&#148;) to develop and commercialize in the
United States gaboxadol, a compound licensed to Lundbeck by a third party that
is currently in Phase III development for the treatment of sleep disorders.
Under the terms of the agreement, Lundbeck will receive an initial payment of
$70.0&nbsp;million and up to $200.0&nbsp;million in additional milestone payments. The
Company and Lundbeck will jointly complete the ongoing Phase III clinical
program, with the Company funding the majority of the remaining development
activities. The Company anticipates that it will file an NDA with the FDA
between late 2006 and mid-2007. Following FDA approval, the companies plan to
co-promote gaboxadol in the United States. Lundbeck will receive a share of
gaboxadol sales in the United States.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On February&nbsp;23, 2004, the Company announced that it had agreed to acquire
Aton Pharma, Inc. (&#147;Aton&#148;), a privately held biotechnology company focusing on
the development of novel treatments for cancer and other serious diseases.
Consideration for the acquisition will consist of upfront and contingent
payments based upon the regulatory filing, and approval and sales of products.
Aton&#146;s clinical pipeline of histone deacetylase inhibitors represents a class
of anti-tumor agents with potential for efficacy based on a novel mechanism of
action. Aton&#146;s lead product candidate, known as suberoylanilide hydroxamic
acid, has been extensively studied in Phase I clinical trials and is currently
in Phase II clinical trials for the treatment of cutaneous T-cell lymphoma.
The Company expects to complete the acquisition of Aton in the first quarter of
2004.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The chart below reflects the Company&#146;s research pipeline as of March&nbsp;1,
2004. Candidates shown in Phase III include specific products. Candidates
shown in Phase I and II include the most advanced compound with a specific
mechanism in a given therapeutic area. Back-up compounds, regardless of their
phase of development, additional indications in the same therapeutic areas and
additional line extensions or formulations for in-line products are not shown.
Preclinical areas shown are those where the Company has initiated Good
Laboratory Practices (&#147;GLP&#148;) studies in compounds with mechanisms distinct from
those in Phase I and II. The Company&#146;s programs are generally designed to
focus on the development of novel medicines to address large, unmet medical
needs.


<P align="center" style="font-size: 10pt">10
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif"></DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="23%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="23%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="23%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="23%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center"><B>Preclinical</B><HR size="1" noshade></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Phase I</B><HR size="1" noshade></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Phase II</B><HR size="1" noshade></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Phase III</B><HR size="1" noshade></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Diabetes</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Diabetes</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;c-3347
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Obesity</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Vaccines</B></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Atherosclerosis</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Obesity</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;c-2735
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;<B>Pediatric Combination</B></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;c-2624
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Alzheimer&#146;s Disease</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;<B>Vaccine</B></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Parkinson&#146;s Disease</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;c-5093
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;c-9136
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;<I>ProQuad</I></TD>
</TR>

<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Atherosclerosis</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Urinary Incontinence</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;<B>Rotavirus</B></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Pain</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;c-8834
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;c-3048
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;<I>RotaTeq</I></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Alzheimer&#146;s Disease</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Respiratory Disease</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;<B>Shingles</B></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Anxiety</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;c-7617
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;c-3885
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;Zoster vaccine</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;c-9138
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Post-Operative Nausea</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;<B>Human Papillomavirus</B></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Osteoporosis</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Multiple Sclerosis</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>and Vomiting</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;HPV vaccine</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;c-6448
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;c-9280</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Cancer</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Pain</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Vaccines</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Diabetes</B></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;c-1246
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;Pediatric Combination</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;MK-0431 (2Q04)</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Rheumatoid Arthritis</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Psychiatric Disease</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;c-9054
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Sleep Disorders</B></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Glaucoma</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Respiratory Disease</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;MK-0928 (Gaboxadol)</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;c-3193</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Antibacterial</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Rheumatoid Arthritis</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;c-4462</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Vaccines</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;c-5997</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="center"></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>AIDS</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;c-2507
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Vaccines</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;HIV vaccine
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>





<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="60%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="23%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="23%">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD colspan="3" valign="top" style="font-size: 8pt" align="center"><B>2003 Submissions</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<BR></TD>
</TR>

<TR valign="bottom">

<TD colspan="3" valign="top" style="font-size: 8pt" align="center"><HR
size="1" noshade></TD>
</TR>


<TR valign="bottom">
    <TD align="left" valign="top"><B>Cardiovascular</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Arthritis / Analgesia</B></TD>
</TR>

<TR valign="bottom">
    <TD align="left" valign="top">&nbsp;&nbsp;<B><I>Vytorin</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;<B><I>Arcoxia</I></B></TD>
</TR>

<TR valign="bottom">
    <TD align="left" valign="top">&nbsp;&nbsp;(Ezetimibe / Simvastatin)
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;(submitted 4Q03)</TD>
</TR>

<TR valign="bottom">
    <TD align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;(submitted 3Q03)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>




<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In February&nbsp;2003, the Company announced that it had discontinued Phase II
clinical trials for its lead GABA-A <FONT face="Symbol">a</FONT>2/<FONT face="Symbol">a</FONT>3 agonist compound for the treatment of
generalized anxiety. The Company is continuing its research in the field of
anxiety through the ongoing study of other GABA agonist molecules. The timing
for the development of these other molecules is not certain.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In April&nbsp;2003, the Company announced that it was discontinuing development
of its lead Phosphodiesterase-4 (PDE-4) inhibitor compound in Phase II clinical
trials for the treatment of asthma and chronic obstructive pulmonary disease
(COPD). The Company is continuing its research in the field of asthma and COPD
through the ongoing study of other PDE-4 inhibitor molecules. The timing for
the development of these other molecules is not certain.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In August&nbsp;2003, the Company announced it had put the Phase I clinical
trials for its lead HIV integrase inhibitor compound on hold. The Company is
also continuing its research in the field of integrase inhibitors through the
ongoing study of other integrase inhibitors. The timing for the development of
these other molecules is not certain.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In November&nbsp;2003, the Company announced that it was discontinuing its
Phase III clinical development program for its substance P antagonist
investigational product, MK-0869, for the treatment of depression. The Phase
III clinical program was halted because the compound failed to demonstrate
efficacy for the treatment of depression. The Company remains committed to its
neuroscience research programs.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Also in November&nbsp;2003, the Company announced that it was discontinuing its
Phase III clinical development program for its investigational product,
MK-0767, for the treatment of diabetes. The Company was


<P align="center" style="font-size: 10pt">11
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="left" style="margin-left: 0%; text-indent: 0%; margin-right: 0%; font-size: 10pt">developing MK-0767 in collaboration with Kyorin Pharmaceutical Co., Ltd. The
clinical program was halted because recent findings in the Company&#146;s long-term
safety assessment program identified a rare form of malignant tumors in mice.
The clinical relevance of these findings in humans is unknown. The Company is
continuing its commitment to diabetes research and is currently studying a
DP-IV inhibitor for diabetes. The Company plans to enter Phase III clinical
trials with this investigational compound in the second quarter of 2004.

<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On February&nbsp;21, 2003, Banyu announced a change of timing with respect to
the filing in Japan of an NDA for rofecoxib (<I>Vioxx</I>). In its press release,
Banyu stated that after reviewing clinical data accumulated to date, and at the
recommendation of the Organization of Pharmaceutical Safety and Research, Banyu
has agreed to conduct additional studies in Japanese patients to further
support the NDA filing. As a result of this decision, the NDA filing which was
originally planned to take place by the end of March&nbsp;2003 has been delayed.
Banyu further stated that it will conduct the additional studies as appropriate
in support of filing the product.

<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On December&nbsp;30, 2003, the Company submitted an NDA to the FDA for <I>Arcoxia</I>.
The Company&#146;s NDA seeks indications for <I>Arcoxia </I>for the treatment of
osteoarthritis, rheumatoid arthritis, chronic low back pain, acute pain,
dysmenorrhea, acute gouty arthritis and ankylosing spondylitis (a painful
condition of the spine). As of January&nbsp;30, 2004, <I>Arcoxia </I>has been launched in
41 countries worldwide in Europe, Latin America and the Asia-Pacific region.
The FDA has informed the Company that the FDA considers January&nbsp;13, 2004 the
effective submission date for the NDA because fiscal year 2003 fees for a
different medicine were not received by December&nbsp;31, 2003. The FDA has
informed the Company that unless the Company is otherwise notified, the NDA
will be accepted for filing on March&nbsp;12, 2004.

<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In November&nbsp;2003, the European Union&#146;s Committee for Proprietary Medicinal
Products concluded its comprehensive review of the COX-2 selective inhibitor
class, which includes <I>Vioxx </I>and <I>Arcoxia</I>, and confirmed that the medicines have
a positive balance of benefits and risks. The French Transparency Commission,
whose responsibilities include recommending drug reimbursement levels in
France, after review has retained its assessment that <I>Vioxx </I>provides a modest
level of improvement relative to non-steroidal anti-inflammatory drugs in terms
of safety.

<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All product or service marks appearing in type form different from that of
the surrounding text are trademarks or service marks owned by or licensed to
Merck &#038; Co., Inc., its subsidiaries or affiliates (including <I>Zetia</I>, a trademark
owned by an entity of the Merck/Schering-Plough Pharmaceuticals partnership),
except as noted. <I>Cozaar </I>and <I>Hyzaar </I>are registered trademarks of E.I. du Pont
de Nemours and Company, Wilmington, DE and <I>Prilosec </I>and <I>Nexium </I>are trademarks
of the AstraZeneca group. The U.S. trademarks for <I>Vasotec </I>and <I>Vaseretic </I>are
owned by Biovail Laboratories Incorporated. The U.S. trademark for <I>Aggrastat </I>is
owned by Guilford Pharmaceuticals Inc.

<P align="left" style="font-size: 10pt"><B>Employees</B>

<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At the end of 2003, the Company had 63,200 employees worldwide, with
33,200 employed in the United States, including Puerto Rico. Approximately 25%
of worldwide employees of the Company are represented by various collective
bargaining groups.

<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In 2003, the Company accelerated its efforts to fundamentally lower its
cost structure through Company-wide initiatives. In October&nbsp;2003, the Company
announced the reduction of 4,400 positions, which is expected to be completed
in 2004. When complete, the cost reductions are expected to generate annual
savings of payroll and benefits costs of $250.0 to $300.0&nbsp;million starting in 2005.

<P align="left" style="font-size: 10pt"><B>Environmental Matters</B>

<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company believes that it is in compliance in all material respects
with applicable environmental laws and regulations. In 2003, the Company
incurred capital expenditures of approximately $41.8&nbsp;million for environmental
protection facilities. The Company is also remediating environmental
contamination resulting from past industrial activity at certain of its sites.
Expenditures for remediation and environmental liabilities were $31.3

<P align="center" style="font-size: 10pt">12
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="left" style="margin-left: 0%; text-indent: 0%; margin-right: 0%; font-size: 10pt">million
in 2003,
and are estimated at $87.0&nbsp;million for the years 2004 through 2008. These
amounts do not consider potential recoveries from insurers or other parties.
The Company has taken an active role in identifying and providing for these
costs, and in management&#146;s opinion, the liabilities for all environmental
matters which are probable and reasonably estimable have been accrued.
Although it is not possible to predict with certainty the outcome of these
environmental matters, or the ultimate costs of remediation, management does
not believe that any reasonably possible expenditures that may be incurred in
excess of those provided should result in a material adverse effect on the
Company&#146;s financial position, results of operations, liquidity or capital
resources.


<P align="left" style="font-size: 10pt"><B>Cautionary Factors that May Affect Future Results</B>



<DIV align="left" style="margin-left: 0%; text-indent: 0%; margin-right: 0%; font-size: 10pt">(Cautionary Statements Under the Private Securities Litigation Reform Act of
1995) </DIV>


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This report and other written reports and oral statements made from time
to time by the Company may contain so-called &#147;forward-looking statements,&#148; all
of which are subject to risks and uncertainties. One can identify these
forward-looking statements by their use of words such as &#147;expects,&#148; &#147;plans,&#148;
&#147;will,&#148; &#147;estimates,&#148; &#147;forecasts,&#148; &#147;projects&#148; and other words of similar
meaning. One can also identify them by the fact that they do not relate
strictly to historical or current facts. These statements are likely to
address the Company&#146;s growth strategy, financial results, product approvals and
development programs. One must carefully consider any such statement and
should understand that many factors could cause actual results to differ
materially from the Company&#146;s forward-looking statements. These factors
include inaccurate assumptions and a broad variety of other risks and
uncertainties, including some that are known and some that are not. No
forward-looking statement can be guaranteed and actual future results may vary
materially. Although it is not possible to predict or identify all such
factors, they may include the following:


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="right">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Generic competition as product patents for several products have recently expired in the United States and other countries,
including product patents for <I>Mevacor </I>(U.S. - 2001),
<I>Prinivil and Prinzide </I>(U.S. - 2001) and <I>Vaseretic </I>(U.S.
- 2001). In
2003, <I>Zocor </I>lost its basic patent protection in Canada and certain countries in Europe, including the United Kingdom and
Germany, and the Company experienced a decline in <I>Zocor </I>sales in those countries. In 2006, <I>Zocor </I>will lose its market
exclusivity in the United States and the Company expects a decline in
U.S. <I>Zocor</I> sales. In addition, the U.S. patent covering
omeprazole, the active ingredient in <I>Prilosec</I>, which the Company supplies exclusively to AstraZeneca LP, expired in 2001,
and a trial court held in October&nbsp;2002 that one generic company&#146;s omeprazole product does not infringe the Company&#146;s
formulation patents with respect to <I>Prilosec</I>. Under an agreement with AstraZeneca, the Company receives supply payments at
predetermined rates on the U.S. sales of certain products by AstraZeneca, most notably <I>Prilosec </I>and <I>Nexium</I>.</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="right">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Increased &#147;brand&#148; competition in therapeutic areas important to the Company&#146;s long-term business performance.</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="right">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The difficulties and uncertainties inherent in new product development. The outcome of the lengthy and complex process of
new product development is inherently uncertain. A candidate can fail at any stage of the process and one or more
late-stage product candidates could fail to receive regulatory approval. New product candidates may appear promising in
development but fail to reach the market because of efficacy or safety concerns, the inability to obtain necessary
regulatory approvals, the difficulty or excessive cost to manufacture and/or the infringement of patents or intellectual
property rights of others. Furthermore, the sales of new products may prove to be disappointing and fail to reach
anticipated levels.</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="right">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pricing pressures, both in the United States and abroad, including rules and practices of managed care groups, judicial
decisions and governmental laws and regulations related to Medicare, Medicaid and health care reform, pharmaceutical
reimbursement and pricing in general.</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="right">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>As the Company previously announced in the fourth quarter of 2003, it has taken actions to lower its cost structure
including the elimination of positions. Those actions will continue in 2004.</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="right">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Changes in government laws and regulations and the enforcement thereof affecting the Company&#146;s business.</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="right">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Efficacy or safety concerns with respect to marketed products, whether or not scientifically justified, leading to product
recalls, withdrawals or declining sales.</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt">13
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<P><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
</TABLE>

<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="right">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Legal factors, including product liability claims, antitrust litigation and governmental investigations, environmental
concerns and patent disputes with branded and generic competitors, any of which could preclude commercialization of
products or negatively affect the profitability of existing products.</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="right">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Lost market opportunity resulting from delays and uncertainties in the approval process of the FDA and foreign regulatory
authorities.</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="right">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Increased focus on privacy issues in countries around the world, including the United States and the EU. In the United
States, federal and state governments have pursued legislative and regulatory initiatives regarding patient privacy,
including federal and recently issued state privacy regulations concerning health information, which have affected the
Company&#146;s operations.</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="right">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Changes in tax laws including changes related to the taxation of foreign earnings, as well as the impact of legislation
capping and ultimately repealing Section&nbsp;936 of the Internal Revenue Code (relating to earnings from the Company&#146;s Puerto
Rican operations).</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="right">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Changes in accounting pronouncements promulgated by standard-setting or regulatory bodies, including the Financial
Accounting Standards Board and the Securities and Exchange Commission, that are adverse to the Company.</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="right">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Economic factors over which the Company has no control, including changes in inflation, interest rates and foreign currency
exchange rates.</TD>
</TR>
</TABLE>

<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This list should not be considered an exhaustive statement of all
potential risks and uncertainties.

<P align="left" style="font-size: 10pt"><B>Geographic Area and Segment Information</B>

<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company&#146;s operations are principally managed on a products basis with
one reportable segment: The Merck Pharmaceutical segment which includes
products marketed either directly or through joint ventures. Merck
Pharmaceutical products consist of therapeutic and preventive agents, sold by
prescription, for the treatment and prevention of human disorders.

<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company&#146;s operations outside the United States are conducted primarily
through subsidiaries. Sales worldwide by subsidiaries outside the United
States were 41% of sales in 2003, and 39% and 37% in 2002 and 2001,
respectively.

<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company&#146;s worldwide business is subject to risks of currency
fluctuations, governmental actions and other governmental proceedings abroad.
The Company does not regard these risks as a deterrent to further expansion of
its operations abroad. However, the Company closely reviews its methods of
operations and adopts strategies responsive to changing economic and political
conditions.

<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In recent years, the Company has been expanding its operations in
countries located in Latin America, the Middle East, Africa, Eastern Europe and
Asia Pacific where changes in government policies and economic conditions are
making it possible for the Company to earn fair returns. Business in these
developing areas, while sometimes less stable, offers important opportunities
for growth over time.

<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial information about geographic areas and operating segments of the
Company&#146;s business is incorporated by reference to pages&nbsp;48 (beginning with the
caption &#147;Segment Reporting&#148;) and&nbsp;49 of the Company&#146;s 2003 Annual Report to
stockholders.

<P align="left" style="font-size: 10pt"><B>Available Information</B>

<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company&#146;s Internet website address is <I>www.merck.com</I>. The Company will
make available, free of charge at the &#147;Investor Information&#148; portion of its
website, its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q,
Current Reports on Form 8-K, and all amendments to those reports filed or
furnished pursuant to Section

<P align="center" style="font-size: 10pt">14
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="left" style="margin-left: 0%; text-indent: 0%; margin-right: 0%; font-size: 10pt">13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, as soon
as reasonably practicable after such reports are electronically filed with, or
furnished to, the Securities and Exchange Commission.

<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company's corporate governance guidelines and the charters of the
Board of Directors' six standing committees are available on the
Company's website at <I>www.merck.com/about/corporategovernance</I>
and all such information is available in print to any stockholder who
requests it from the Company.

<!-- link2 "Item&nbsp;2. Properties" -->
<DIV align="left"><A NAME="002"></A></DIV>

<P align="left" style="font-size: 10pt"><B>Item&nbsp;2. Properties.</B>

<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company&#146;s corporate headquarters is located in Whitehouse Station, New
Jersey. The Company&#146;s pharmaceutical business is conducted through divisional
headquarters located in Upper Gwynedd and West Point, Pennsylvania. Principal
research facilities for human health products are located in Rahway, New Jersey
and West Point. The Company also has production facilities for human health
products at nine locations in the United States and Puerto Rico. Branch
warehouses provide services throughout the country. Outside the United States,
through subsidiaries, the Company owns or has an interest in manufacturing
plants or other properties in Australia, Canada, Japan, Singapore,
South Africa,
and other countries in Western Europe, Central and South America, and Asia.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Capital expenditures for 2003 were $1,915.9&nbsp;million compared with $2,128.1
million for 2002. In the United States, these amounted to $1,307.8&nbsp;million for
2003 and $1,565.2&nbsp;million for 2002. Abroad, such expenditures amounted to
$608.1&nbsp;million for 2003 and $562.9&nbsp;million for 2002.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company and its subsidiaries own their principal facilities and
manufacturing plants under titles which they consider to be satisfactory. The
Company considers that its properties are in good operating condition and that
its machinery and equipment have been well maintained. Plants for the
manufacture of products are suitable for their intended purposes and have
capacities and projected capacities adequate for current and projected needs
for existing Company products. Some capacity of the plants is being converted,
with any needed modification, to the requirements of newly introduced and
future products.

<!-- link2 "Item&nbsp;3. Legal Proceedings" -->
<DIV align="left"><A NAME="003"></A></DIV>

<P align="left" style="font-size: 10pt"><B>Item&nbsp;3. Legal Proceedings.</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company is involved in various claims and legal proceedings of a
nature considered normal to its business, including product liability,
intellectual property, and commercial litigation, as well as additional matters
such as antitrust actions.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beginning in 1993, the Company was named in a number of antitrust suits,
certain of which were certified as class actions, instituted by most of the
nation&#146;s retail pharmacies and consumers in several states, alleging antitrust
violations. In 1994, these actions, except for those pending in state courts,
were consolidated for pre-trial purposes in the federal court in Chicago,
Illinois. In 1996, the Company and several other defendants settled the
federal class action, which represented the single largest group of claims.
Since that time, the Company has settled substantially all of the remaining
cases on satisfactory terms. The Company has not engaged in any conspiracy and
no admission of wrongdoing was made nor was included in any settlement
agreements. While it is not feasible to predict the final outcome of the few
remaining cases, in the opinion of the Company, these proceedings should not
ultimately result in any liability which would have a material adverse effect
on the Company&#146;s financial position, results of operations or liquidity.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As previously disclosed, the Company has been advised by the U.S.
Department of Justice that it is investigating marketing and selling activities
of the Company and other pharmaceutical manufacturers. In connection with the
investigation, as previously disclosed, the government served a subpoena on the
Company for the production of documents related to Company marketing and sales
activities. The subpoena seeks substantially the same information as the
government has previously sought. The Company will be working with the
government to respond appropriately to this subpoena and other informational
requests. The Company has also received a Civil Investigative Demand (&#147;CID&#148;)
from the Attorney General of Texas. The CID seeks the production of documents
and other information regarding the Company&#146;s marketing and selling activities
relating to Texas. The Company is working with the Texas Attorney General&#146;s
office to respond appropriately to the CID.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As previously disclosed, the Company was joined in ongoing litigation
alleging manipulation by pharmaceutical manufacturers of Average Wholesale
Prices (&#147;AWP&#148;), which are sometimes used in calculations that determine public
and private sector reimbursement levels. In 2002, the Judicial Panel on
Multi-District Litigation


<P align="center" style="font-size: 10pt">15
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="left" style="margin-left: 0%; text-indent: 0%; margin-right: 0%; font-size: 10pt">ordered the transfer and consolidation of all pending federal AWP cases to
federal court in Boston, Massachusetts. Plaintiffs filed one consolidated
class action complaint, which aggregated the claims previously filed in various
federal district court actions and also expanded the number of manufacturers to
include some which, like the Company, had not been defendants in any prior
pending case. In May&nbsp;2003, the court granted the Company&#146;s motion to dismiss
the consolidated class action and dismissed the Company from the class action
case. Subsequent to the Company&#146;s dismissal, the plaintiffs filed an amended
consolidated class action complaint, which did not name the Company as a
defendant. The Company and thirty other pharmaceutical manufacturers remain
defendants in three similar complaints pending in federal court in
Massachusetts filed by the New York Counties of Suffolk, Rockland and
Westchester. The Company believes that these lawsuits are without merit and is
vigorously defending against them.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As previously disclosed, in January&nbsp;2003, the U.S. Department of Justice
notified the federal court in New Orleans, Louisiana that it was not going to
intervene in a pending Federal False Claims Act case that was filed under seal
in December&nbsp;1999 against the Company. The court issued an order unsealing the
complaint, which was filed by a physician in Louisiana, and ordered that the
complaint be served. The complaint alleges that the Company&#146;s discounting of
<I>Pepcid </I>in certain Louisiana hospitals led to increases in costs to Medicaid.
The Company believes that the complaint is without merit and will vigorously
defend against it.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Federal and state lawsuits involving numerous individual claims, as well
as some putative class actions, have been filed against the Company with
respect to <I>Vioxx</I>. Some of the lawsuits also name as a defendant Pfizer Inc.,
which markets a competing product. Certain of the lawsuits include allegations
regarding gastrointestinal bleeding, cardiovascular events and kidney damage.
The lawsuits have been filed in federal courts as well as in a number of state
courts. While cases in other jurisdictions are proceeding separately, the
actions filed in the state courts of California and New Jersey have been
transferred to a single judge in each state for coordinated proceedings. The
Company anticipates that one or more of the lawsuits in various jurisdictions
may go to trial in the first half of 2004. Litigation is inherently subject to
uncertainties and no assurance can be given on the outcome of any given trial.
However, the Company believes that these lawsuits are without merit and will
vigorously defend against them.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A number of purported class action lawsuits have been filed by several
individual shareholders in the United States District Court for the Eastern
District of Louisiana naming as defendants the Company and several current or
former officers of the Company, and alleging that the defendants made false and
misleading statements regarding the Company&#146;s drug <I>Vioxx </I>in violation of the
federal securities laws. The plaintiffs request certification of a class of
purchasers of the Company&#146;s common stock between May&nbsp;22, 1999 and October&nbsp;22,
2003, and seek unspecified compensatory damages and the costs of suit,
including attorney fees. The Company believes that these lawsuits are without
merit and will vigorously defend against them.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company is a party in claims brought under the Consumer Protection Act
of 1987 in the United Kingdom, which allege that certain children suffer from a
variety of conditions as a result of being vaccinated with various bivalent
vaccines for measles and rubella and/or trivalent vaccines for measles, mumps
and rubella, including the Company&#146;s <I>M-M-R </I>II. Other pharmaceutical companies
have also been sued. The claimants allege various adverse consequences,
including autism, with or without inflammatory bowel disease, epilepsy,
diabetes, encephalitis, encephalopathy and chronic fatigue syndrome. In
connection with those claims, eight lead cases had been selected for a trial
which was scheduled to commence in April&nbsp;2004: two against the Company, and
six against other pharmaceutical companies. The trial of the eight cases is
initially limited to issues of causation and defect on the conditions of
autistic spectrum disorders, with or without inflammatory bowel disease. In
early September&nbsp;2003, the Legal Services Commission announced its decision to
withdraw public funding of the litigation brought by the claimants. This
decision was confirmed on appeal by the Funding Review Committee on September
30, 2003. The April&nbsp;2004 trial date has been vacated and the claims stayed
pending the outcome of a February&nbsp;2004 hearing on the judicial review of the
funding withdrawal decision. The Company believes that these lawsuits are
without merit and will vigorously defend against them.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company is also a party to individual and class action product
liability lawsuits and claims in the United
States involving pediatric vaccines (i.e., hepatitis B vaccine and
haemophilus influenza type b vaccine) that



<P align="center" style="font-size: 10pt">16
</DIV>


<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<P align="left"><FONT size="2">contained thimerosal, a preservative used in vaccines. Other defendants
include vaccine manufacturers who produced pediatric vaccines containing
thimerosal as well as manufacturers of thimerosal. In these actions, the
plaintiffs allege, among other things, that they have suffered neurological and
other injuries as a result of having thimerosal introduced into their
developing bodies. The Company has been successful in having many of these
cases either dismissed or stayed on the ground that the National Vaccine Injury
Compensation Program (&#147;NVICP&#148;) prohibits any person from filing or maintaining
a civil action seeking damages against a vaccine manufacturer for
vaccine-related injuries unless a petition is first filed in the United States
Court of Federal Claims. A number of similar cases (<I>M-M-R </I>II alone and/or
thimerosal-containing vaccines) have been filed in the United States Court of
Federal Claims under the NVICP for a determination first on general causation
issues. The Company believes that these lawsuits and claims are without merit
and will vigorously defend against them in the proceedings in which it is a
party.
</FONT>
<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From time to time, generic manufacturers of pharmaceutical products file
Abbreviated New Drug Applications (&#147;ANDAs&#148;) with the FDA seeking to market
generic forms of Company products prior to the expiration of relevant patents
owned by the Company. Generic pharmaceutical manufacturers have submitted
ANDAs to the FDA seeking to market in the United States a generic form of
<I>Fosamax</I>, <I>Prilosec </I>and <I>Vioxx </I>prior to the expiration of the Company&#146;s (and
AstraZeneca&#146;s in the case of <I>Prilosec) </I>patents concerning these products. The
generic companies&#146; ANDAs generally include allegations of non-infringement,
invalidity and unenforceability of the patents. Generic manufacturers have
received FDA approval to market a generic form of <I>Prilosec</I>. The Company has
filed patent infringement suits in federal court against companies filing ANDAs
for generic alendronate and rofecoxib, and AstraZeneca and the Company have
filed patent infringement suits in federal court against companies filing ANDAs
for generic omeprazole. Similar patent challenges exist in certain foreign
jurisdictions. The Company intends to vigorously defend its patents, which it
believes are valid, against infringement by generic companies attempting to
market products prior to the expiration dates of such patents. As with any
litigation, there can be no assurance of the outcomes, which, if adverse, could
result in significantly shortened periods of exclusivity for these products.
</FONT>
<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A trial in the United States with respect to the alendronate daily product
concluded in November 2001. In November 2002, a decision was issued by the
U.S. District Court in Delaware finding the Company&#146;s patent valid and
infringed. On October&nbsp;30, 2003, the U.S. Court of Appeals for the Federal
Circuit affirmed the validity and infringement of the Company&#146;s basic U.S.
patent covering the use of alendronate in any form. A request for rehearing
was denied. A trial in the United States involving the alendronate weekly
product was held in March 2003. On August&nbsp;28, 2003, the U.S. District Court in
Delaware, upheld the validity of the Company&#146;s U.S. patent covering the weekly
administration of alendronate. As a result of the court&#146;s decision, the patent
is valid and infringed by Teva Pharmaceuticals USA, Inc.&#146;s (&#147;Teva&#148;) Abbreviated
New Drug Application filing. The court&#146;s decision has been appealed by Teva.
</FONT>
<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In January 2003, the High Court of Justice for England and Wales held that
patents of the Company protecting the alendronate daily and weekly products
were invalid in the United Kingdom. On November&nbsp;6, 2003, the Court of Appeals
of England and Wales affirmed the ruling by the High Court of Justice for
England and Wales. Protection against generic companies referencing the
Company&#146;s data for weekly alendronate in the United Kingdom may be available
under the provisions of the law which grant a period of exclusivity to the
original submitter of such data. A generic company has sought judicial review
of a decision by the Licensing Authority in the United Kingdom that it cannot
rely upon the Company&#146;s weekly alendronate data to seek approval of a generic
alendronate 70 mg product until ten years after approval of the Company&#146;s
weekly alendronate product (which was granted in 2000). The Company has been
served as an interested party and intends to take appropriate action to protect
its rights.
</FONT>
<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the case of omeprazole, the trial court in the United States rendered
an opinion in October 2002 upholding the validity of the Company&#146;s and
AstraZeneca&#146;s patents covering the stabilized formulation of omeprazole and
ruling that one defendant&#146;s omeprazole product did not infringe those patents.
The other three defendants&#146; products were found to infringe the formulation
patents. In December 2003, the U.S. Court of Appeals for the Federal Circuit
affirmed the decision of the trial court. With respect to certain other
generic manufacturers&#146; omeprazole products, no trial date has yet been set.
</FONT>
<P align="center"><FONT size="2">17</FONT>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>
<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the case of rofecoxib, an ANDA has been filed including allegations of
non-infringement, invalidity and unenforceability of the Company&#146;s rofecoxib
patents. As previously disclosed, the Company filed a patent infringement
lawsuit in the District Court of Delaware in August 2003. Trial has been set
for October 2005.
</FONT>
<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As previously disclosed, the Company has been named as a defendant in a
number of purported class action lawsuits, which have been consolidated before
a single judge and in a shareholder derivative action, both of which involve
claims related to the Company&#146;s revenue recognition practice for retail
copayments paid by individuals to whom Medco Health provides pharmaceutical
benefits. The class action lawsuit was amended to add claims against the
Company and Medco Health and certain of their officers and directors relating
to rebates received by Medco Health and Medco Health&#146;s independent status. The
shareholder derivative action was amended to add Arthur Andersen LLP as a
defendant and to add certain new allegations, which relate to claims that
certain individual defendants breached their fiduciary duty by failing to
prevent the conduct at issue in the previously disclosed Gruer Cases, discussed
below, the antitrust claims pending in the Northern District of Illinois, and
the <I>qui tam </I>actions in which the U.S. Attorney&#146;s office for the Eastern
District of Pennsylvania has intervened against Medco Health. The complaint
seeks monetary damages from those Company directors who are defendants in the
lawsuit in an unspecified amount as well as injunctive and other relief. As
part of the spin-off of Medco Health, Medco Health assumed responsibility for a
portion of potential damages or settlement payments paid, if any, in connection
with this litigation. The Company believes that these lawsuits are without
merit and will vigorously defend against them.
</FONT>
<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior to the spin-off of Medco Health, the Company and Medco Health agreed
to settle, on a class action basis, a series of lawsuits asserting violations
of the Employee Retirement Income Security Act (&#147;ERISA&#148;). The Company, Medco
Health and certain plaintiffs&#146; counsel filed the settlement agreement with the
federal district court in New York, where cases commenced by a number of
plaintiffs, including participants in a number of pharmaceutical benefit plans
for which Medco Health is the pharmacy benefit manager, as well as trustees of
such plans, have been consolidated. The proposed class settlement has been
agreed to by plaintiffs in five of the cases (the &#147;Gruer Cases&#148;) filed against
Medco Health and the Company. Under the proposed settlement, the Company and
Medco Health have agreed to pay a total of $42.5&nbsp;million, and Medco Health has
agreed to modify certain business practices or to continue certain specified
business practices for a period of five years. The financial compensation is
intended to benefit members of the settlement class, which includes ERISA plans
for which Medco Health administered a pharmacy benefit at any time since
December&nbsp;17, 1994. In 2003, the court preliminarily approved the settlement
and has held a hearing to hear objections to the fairness of the proposed
settlement from class member representatives. Currently, certain class member
plans have indicated that they will not participate in the settlement. The
court has not yet approved the settlement or determined the number of class
member plans that have properly elected not to participate in the settlement,
if approved. The settlement becomes final only if and when the district court
grants final approval and all appeals have been resolved. Medco Health and the
Company agreed to the proposed settlement in order to avoid the significant
cost and distraction of protracted litigation.
</FONT>
<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Gruer Cases, which are similar to claims pending against other
pharmaceutical benefit managers, alleged that Medco Health was an ERISA
&#147;fiduciary&#148; and that the Company was a &#147;party-in-interest&#148; within the meaning
of ERISA. The plaintiffs asserted that the Company and Medco Health had
breached duties and engaged in &#147;prohibited transactions&#148; as a result of filling
prescriptions with the Company&#146;s drugs to increase the Company&#146;s market share,
among other things. The plaintiffs demanded that Medco Health and the Company
disgorge any unlawfully obtained profits and other relief.
</FONT>
<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition, among the cases consolidated in New York, one plaintiff has
also alleged, based on essentially the same factual allegations as the Gruer
Cases, that Medco Health and the Company have violated federal and state
racketeering laws. A different plaintiff, seeking to represent California
citizens, has alleged that Medco Health and the Company have violated
California unfair competition law. An attorney for one of the plaintiffs has
indicated that it may assert claims against Medco Health, the Company and
others to allege violations of the Sherman Act, the Clayton Act and various
state antitrust laws based on alleged conspiracies to suppress price
competition and unlawful combinations allegedly resulting in higher
pharmaceutical prices.
</FONT>
<P align="center"><FONT size="2">18</FONT>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>
<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;After the spin-off of Medco Health, Medco Health assumed substantially all
of the liability exposure for the matters discussed in the foregoing three
paragraphs. The Company believes that these cases, which are being defended by
Medco Health, are without merit.
</FONT>
<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In December 2003, the Virginia Department of Environmental Quality
(&#147;VADEQ&#148;) issued a Notice of Violation to the Company&#146;s Elkton, Virginia
facility for air permit limit exceedances reported by the facility as a result
of performance testing of a process train. The Company is currently in
discussions with VADEQ and believes that its discussions will result in capital
improvements together with monetary sanctions which will be immaterial but will
exceed $100,000.
</FONT>
<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company is a party to a number of proceedings brought under the
Comprehensive Environmental Response, Compensation and Liability Act, commonly
known as Superfund and other federal and state equivalents. These proceedings
seek to require the operators of hazardous waste disposal facilities,
transporters of waste to the sites and generators of hazardous waste disposed
of at the sites to clean up the sites or, to reimburse the government for
cleanup costs. The Company has been made a party to these proceedings as an
alleged generator of waste disposed of at the sites. In each case, the
government alleges that the defendants are jointly and severally liable for the
cleanup costs. Although joint and several liability is alleged, these
proceedings are frequently resolved so that the allocation of cleanup costs
among the parties more nearly reflects the relative contributions of the
parties to the site situation. The Company&#146;s potential liability varies
greatly from site to site. For some sites the potential liability is <I>de
minimis </I>and for others the costs of cleanup have not yet been determined.
While it is not feasible to predict the outcome of many of these proceedings
brought by federal or state agencies or private litigants, in the opinion of
the Company, such proceedings should not ultimately result in any liability
which would have a material adverse effect on the financial position, results
of operations, liquidity or capital resources of the Company. The Company has
taken an active role in identifying and providing for these costs and such
amounts do not include any reduction for anticipated recoveries of cleanup
costs from insurers, former site owners or operators or other recalcitrant
potentially responsible parties.
</FONT>
<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There are various other legal proceedings, principally product liability
and intellectual property suits involving the Company, which are pending.
While it is not feasible to predict the outcome of these proceedings or the
proceedings discussed above, in the opinion of the Company, all such
proceedings are either adequately covered by insurance or, if not so covered,
should not ultimately result in any liability that would have a material
adverse effect on the financial position, liquidity or results of operations of
the Company. In addition, from time to time, federal or state regulators seek
information about practices in the pharmaceutical industry. While it is not
feasible to predict the outcome of any requests for information, the Company
does not expect such inquiries to have a material adverse effect on the
financial position, liquidity or results of operations of the Company.
</FONT>
<!-- link2 "Item&nbsp;4. Submission of Matters to a Vote of Security Holders" -->
<DIV align="left"><A NAME="004"></A></DIV>
<P align="left"><FONT size="2"><B>Item&nbsp;4. Submission of Matters to a Vote of Security Holders.</B>
</FONT>

<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Not applicable.
</FONT>


<P align="center"><FONT size="2">19</FONT>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<P align="left"><FONT size="2"><B>Executive Officers of the Registrant (as of March&nbsp;9, 2004)</B>
</FONT>

<P align="left"><FONT size="2">RAYMOND V. GILMARTIN &#151; Age 63</FONT>

<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="85%">
<TR valign="bottom">
    <TD width="100%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">June, 1994 &#151; Chairman of the Board (since November, 1994), President
and Chief Executive Officer</FONT></DIV></TD>
</TR>
</TABLE>
</CENTER>

<P align="left"><FONT size="2">DAVID W. ANSTICE &#151; Age 55
</FONT>

<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="85%">
<TR valign="bottom">
    <TD width="100%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">January, 2003 &#151; President, Human Health  &#151;  responsible for the Company&#146;s
prescription drug business in Japan, Latin America, Canada, Australia,
New Zealand and the Company&#146;s joint venture relationship with
Schering-Plough</FONT></DIV></TD>
</TR>
</TABLE>
</CENTER>

<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="85%">
<TR valign="bottom">
    <TD width="100%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">March, 2001 &#151; President, The Americas and U.S. Human Health &#151; responsible
for one of the two prescription drug divisions comprising U.S. Human
Health, as well as the Company&#146;s prescription drug business in Canada
and Latin America, and the Company&#146;s joint venture relationship with
Schering-Plough</FONT></DIV></TD>
</TR>
</TABLE>
</CENTER>

<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="85%">
<TR valign="bottom">
    <TD width="100%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">January, 1997 &#151; President, Human Health-The Americas &#151; responsible for the
Company&#146;s human health business in the United States, Canada and Latin
America</FONT></DIV></TD>
</TR>
</TABLE>
</CENTER>

<P align="left"><FONT size="2">MARCIA J. AVEDON &#151; Age 42
</FONT>

<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="85%">
<TR valign="bottom">
    <TD width="100%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">January, 2003 &#151; Senior Vice President, Human Resources</FONT></DIV></TD>
</TR>
</TABLE>
</CENTER>

<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="85%">
<TR valign="bottom">
    <TD width="100%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">September, 2002 &#151; Vice President, Talent Management and Organization
Effectiveness</FONT></DIV></TD>
</TR>
</TABLE>
</CENTER>

<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="85%">
<TR valign="bottom">
    <TD width="100%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">Prior to September, 2002, Dr.&nbsp;Avedon held several senior human
resources positions (1995 to 2002) at Honeywell International
(diversified manufacturing and technology company)</FONT></DIV></TD>
</TR>
</TABLE>
</CENTER>

<P align="left"><FONT size="2">RICHARD T. CLARK &#151; Age 58
</FONT>

<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="85%">
<TR valign="bottom">
    <TD width="100%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">June, 2003 &#151; President, Merck Manufacturing Division &#151; responsible for
the Company&#146;s manufacturing, information services and operational
excellence organizations worldwide</FONT></DIV></TD>
</TR>
</TABLE>
</CENTER>

<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="85%">
<TR valign="bottom">
    <TD width="100%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">January, 2003 &#151; Chairman, President and Chief Executive Officer, Medco
Health Solutions, Inc. (Medco Health), formerly a wholly-owned
subsidiary of the Company</FONT></DIV></TD>
</TR>
</TABLE>
</CENTER>

<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="85%">
<TR valign="bottom">
    <TD width="100%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">January, 2000 &#151; President, Medco Health</FONT></DIV></TD>
</TR>
</TABLE>
</CENTER>

<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="85%">
<TR valign="bottom">
    <TD width="100%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">June, 1997 &#151; Executive Vice President/Chief Operating Officer, Medco
Health</FONT></DIV></TD>
</TR>
</TABLE>
</CENTER>

<P align="left"><FONT size="2">CELIA A. COLBERT &#151; Age 47
</FONT>

<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="85%">
<TR valign="bottom">
    <TD width="100%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">January, 1997 &#151; Vice President, Secretary (since September, 1993) and
Assistant General Counsel (since November, 1993)</FONT></DIV></TD>
</TR>
</TABLE>
</CENTER>

<P align="left"><FONT size="2">CAROLINE DORSA &#151; Age 44
</FONT>

<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="85%">
<TR valign="bottom">
    <TD width="100%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">August, 2002 &#151; Vice President and Treasurer &#151; responsible for the Company&#146;s
treasury and tax functions, and for providing financial support for
the Merck Manufacturing and Merck Research Laboratories Divisions as
well as Human Resources</FONT></DIV></TD>
</TR>
</TABLE>
</CENTER>

<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="85%">
<TR valign="bottom">
    <TD width="100%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">September, 1999 &#151; Vice President and Treasurer &#151; responsible for the
Company&#146;s treasury and tax functions and for providing financial
support for the Asia Pacific Division</FONT></DIV></TD>
</TR>
</TABLE>
</CENTER>

<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="85%">
<TR valign="bottom">
    <TD width="100%">&nbsp;</TD>
</TR>
<TR valign="bottom">

<TD><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">February,
1999 &#151; Vice President and Treasurer (since January,
1994)&nbsp;&#151;&nbsp;responsible for the Company&#146;s treasury and tax functions</FONT></DIV></TD>
</TR>
</TABLE>
</CENTER>

<P align="center"><FONT size="2">20</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<P align="left"><FONT size="2">KENNETH C. FRAZIER &#151; Age 49
</FONT>

<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="85%">
<TR valign="bottom">
    <TD width="100%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">December, 1999 &#151; Senior Vice President and General Counsel &#151; responsible
for legal and public affairs functions and The Merck Company
Foundation (a not-for-profit charitable organization affiliated with
the Company)</FONT></DIV></TD>
</TR>

<TR valign="bottom">
    <TD ><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">&nbsp;</FONT></DIV></TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">January, 1999 &#151; Vice President and Deputy General Counsel</FONT></DIV></TD>
</TR>
</TABLE>
</CENTER>
<P align="left"><FONT size="2">RICHARD C. HENRIQUES JR. &#151; Age 48
</FONT>

<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="85%">
<TR valign="bottom">
    <TD width="100%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">August, 2002 &#151; Vice President, Controller &#151; responsible for the Corporate
Controller&#146;s Group and providing financial support for the Human
Health operations in the United States, Canada, Latin America, Europe,
the Middle East, Africa, Japan, and Australia/New Zealand and the
Merck Vaccine Division (MVD)</FONT></DIV></TD>
</TR>

<TR valign="bottom">
    <TD ><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">&nbsp;</FONT></DIV></TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">November, 2000 &#151; Vice President, Controller &#151; responsible for the Corporate
Controller&#146;s Group and providing financial support for U.S. Human
Health, Canada and Latin America (The Americas) and MVD</FONT></DIV></TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">&nbsp;</FONT></DIV></TD>
</TR>

<TR valign="bottom">

<TD><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">February,
1999 &#151; Vice President, Controller (since January, 1997) &#151; responsible for the Corporate
Controller&#146;s Group and providing financial support for The Americas</FONT></DIV></TD>
</TR>
</TABLE>
</CENTER>
<P align="left"><FONT size="2">PETER S. KIM &#151; Age 45
</FONT>

<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="85%">
<TR valign="bottom">
    <TD width="100%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">January, 2003 &#151; President, Merck Research Laboratories (MRL)</FONT></DIV></TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">&nbsp;</FONT></DIV></TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">February, 2001 &#151; Executive Vice President, Research and Development, MRL</FONT></DIV></TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">&nbsp;</FONT></DIV></TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">Prior to February, 2001, Dr.&nbsp;Kim served as Member of the Whitehead
Institute (1985 &#150; 2001), Professor of Biology at the Massachusetts
Institute of Technology (1988 &#150; 2001), and Investigator of the Howard
Hughes Medical Institute (1990 &#150; 2001)</FONT></DIV></TD>
</TR>
</TABLE>
</CENTER>
<P align="left"><FONT size="2">JUDY C. LEWENT &#151; Age 55
</FONT>

<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="85%">
<TR valign="bottom">
    <TD width="100%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">January, 2003 &#151; Executive Vice President, Chief Financial Officer and
President, Human Health Asia &#151; responsible for financial and corporate
development functions, internal auditing, corporate licensing, the
Company&#146;s prescription drug business in Asia North and Asia South, the
Company&#146;s joint venture relationships, and Merck Capital Ventures,
LLC, a subsidiary of the Company</FONT></DIV></TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">&nbsp;</FONT></DIV></TD>
</TR>

<TR valign="bottom">

<TD><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">February,
2001 &#151; Executive Vice President and Chief Financial Officer
&#151;
responsible for financial and corporate development functions,
internal auditing, corporate licensing, the Company&#146;s joint venture
relationships, and Merck Capital Ventures, LLC</FONT></DIV></TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">&nbsp;</FONT></DIV></TD>
</TR>

<TR valign="bottom">

<TD><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">November,
2000 &#151; Senior Vice President and Chief Financial Officer &#151;
responsible for financial and corporate development functions,
internal auditing, corporate licensing, the Company&#146;s joint venture
relationships, and Merck Capital Ventures, LLC</FONT></DIV></TD>
</TR>

<TR valign="bottom">
    <TD colspan="2"><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">&nbsp;</FONT></DIV></TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">January, 1997 &#151; Senior Vice President (since January, 1993) and Chief
Financial Officer (since April, 1990) &#151;  responsible for financial and
corporate development functions, internal auditing and the Company&#146;s
joint venture relationships</FONT></DIV></TD>
</TR>
</TABLE>
</CENTER>
<P align="left"><FONT size="2">ADEL MAHMOUD &#151; Age 62
</FONT>

<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="85%">
<TR valign="bottom">
    <TD width="100%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">May, 1999 &#151; President, Merck Vaccines</FONT></DIV></TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">&nbsp;</FONT></DIV></TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">November, 1998 &#151; Executive Vice President, Merck Vaccines</FONT></DIV></TD>
</TR>
</TABLE>
</CENTER>
<P align="center"><FONT size="2">21</FONT>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<P align="left"><FONT size="2">MARGARET G. MCGLYNN &#151; Age 44
</FONT>

<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="85%">
<TR valign="bottom">
    <TD width="100%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">January, 2003 &#151; President, U.S. Human Health &#151; responsible for one of the
two prescription drug divisions (hospital and specialty product
franchises) comprising U.S. Human Health (USHH), and the Managed Care
Group of USHH</FONT></DIV></TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">&nbsp;</FONT></DIV></TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">August, 2001 &#151; Executive Vice President, Customer Marketing and Sales, USHH</FONT></DIV></TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">&nbsp;</FONT></DIV></TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">November, 1998 &#151; Senior Vice President, Worldwide Human Health Marketing</FONT></DIV></TD>
</TR>
</TABLE>
</CENTER>

<P align="left"><FONT size="2">BRADLEY T. SHEARES &#151; Age 47
</FONT>


<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="85%">
<TR valign="bottom">
    <TD width="100%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">January, 2003 &#151; President, U.S. Human Health &#151; responsible for one of the
two prescription drug divisions (primary care product franchises)
comprising U.S. Human Health (USHH)</FONT></DIV></TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">&nbsp;</FONT></DIV></TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">March, 2001 &#151; President, U.S. Human Health &#151; responsible for one of the two
prescription drug divisions (hospital and specialty product
franchises) comprising USHH</FONT></DIV></TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">&nbsp;</FONT></DIV></TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">July, 1998 &#151; Vice President, Hospital Marketing and Sales, USHH</FONT></DIV></TD>
</TR>
</TABLE>
</CENTER>
<P align="left"><FONT size="2">JOAN E. WAINWRIGHT &#151; Age 43
</FONT>


<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="85%">
<TR valign="bottom">
    <TD width="100%">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD><FONT size="2">
January, 2001 &#151; Vice President, Public Affairs</FONT></TD>
</TR>
<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
    <TD><FONT size="2">June, 2000 &#151; Vice President, Corporate Communications, Public Affairs</FONT></TD>
</TR>
<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
    <TD><FONT size="2">Prior to June, 2000, Ms.&nbsp;Wainwright was Deputy Commissioner for
Communications at the U.S. Social Security Administration (1994 &#150;
2000)</FONT></TD>
</TR>
</TABLE>
</CENTER>

<P align="left"><FONT size="2">PER WOLD-OLSEN &#151; Age 56
</FONT>

<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="85%">
<TR valign="bottom">
    <TD width="100%">&nbsp;</TD>
</TR>
<TR valign="bottom">


<TD><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">January,
1997 &#151; President, Human Health-Europe, Middle East &#038; Africa
&#151;
responsible for the Company&#146;s prescription drug business in Europe,
the Middle East and Africa and worldwide human health marketing</FONT></DIV></TD>
</TR>
</TABLE>
</CENTER>

<P align="left"><FONT size="2">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
All officers listed above serve at the pleasure of the Board of
Directors.
None of these officers was elected pursuant to any arrangement or
understanding between the officer and the Board. There are no family
relationships among the officers listed above.
</FONT>

<P align="center"><FONT size="2">22</FONT>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<!-- link1 "PART II" -->
<DIV align="left"><A NAME="005"></A></DIV>
<P align="center"><FONT size="2"><B>PART II</B>
</FONT>

<!-- link2 "Item&nbsp;5. Market for Registrant&#146;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities" -->
<DIV align="left"><A NAME="006"></A></DIV>
<P align="left"><FONT size="2"><B>Item&nbsp;5. Market for Registrant&#146;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</B>
</FONT>

<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The required information on market information and dividends is
incorporated by reference to page 29 of the Company&#146;s 2003 Annual Report to
stockholders and the required information on the number of holders of the
Company&#146;s common stock is incorporated by reference to page 52 of the Company&#146;s
2003 Annual Report to Stockholders.
</FONT>
<!-- link2 "Item&nbsp;6. Selected Financial Data" -->
<DIV align="left"><A NAME="007"></A></DIV>
<P align="left"><FONT size="2"><B>Item&nbsp;6. Selected Financial Data.</B>
</FONT>

<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The information required for this item is incorporated by reference to the
data for the last five fiscal years of the Company included under Results for
Year and Year-End Position in the Selected Financial Data table on page 52 of
the Company&#146;s 2003 Annual Report to stockholders.
</FONT>
<!-- link2 "Item&nbsp;7. Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations" -->
<DIV align="left"><A NAME="008"></A></DIV>
<P align="left"><FONT size="2"><B>Item&nbsp;7. Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.</B>
</FONT>

<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The information required for this item is incorporated by reference to
pages 16 through 29 of the Company&#146;s 2003 Annual Report to stockholders.
</FONT>
<!-- link2 "Item&nbsp;7A. Quantitative and Qualitative Disclosures About Market Risk" -->
<DIV align="left"><A NAME="009"></A></DIV>
<P align="left"><FONT size="2"><B>Item&nbsp;7A. Quantitative and Qualitative Disclosures About Market Risk.</B>
</FONT>

<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The information required for this item is incorporated by reference to
pages 24 (beginning with the caption &#147;Analysis of Liquidity and Capital
Resources&#148;) to 26 of the Company&#146;s 2003 Annual Report to stockholders.
</FONT>
<!-- link2 "Item&nbsp;8. Financial Statements and Supplementary Data" -->
<DIV align="left"><A NAME="010"></A></DIV>
<P align="left"><FONT size="2"><B>Item&nbsp;8. Financial Statements and Supplementary Data.</B>
</FONT>

<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp; Financial Statements</B>
</FONT>
<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The consolidated balance sheet of Merck &#038; Co., Inc. and subsidiaries as of
December&nbsp;31, 2003 and 2002, and the related consolidated statements of income,
of retained earnings, of comprehensive income and of cash flows for each of the
three years in the period ended December&nbsp;31, 2003, and the report dated
February&nbsp;20, 2004 of PricewaterhouseCoopers LLP, independent auditors, are
incorporated by reference to pages 30 through 49 and page 50, respectively, of
the Company&#146;s 2003 Annual Report to stockholders.
</FONT>
<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp; Supplementary Data</B>
</FONT>
<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Selected quarterly financial data for 2003 and 2002 are incorporated by
reference to the data contained in the Condensed Interim Financial Data table
on page 29 of the Company&#146;s 2003 Annual Report to stockholders.
</FONT>
<!-- link2 "Item&nbsp;9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure" -->
<DIV align="left"><A NAME="011"></A></DIV>
<P align="left"><FONT size="2"><B>Item&nbsp;9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</B>
</FONT>

<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Not
applicable.
</FONT>
<!-- link2 "Item&nbsp;9A. Controls and Procedures" -->
<DIV align="left"><A NAME="012"></A></DIV>
<P align="left"><FONT size="2"><B>Item&nbsp;9A. Controls and Procedures.</B>
</FONT>

<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Management of the Company, with the participation of its Chief Executive
Officer and Chief Financial Officer, evaluated the effectiveness of the
Company&#146;s disclosure controls and procedures. Based on their evaluation, as of
the end of the period covered by this Form&nbsp;10-K, the Company&#146;s Chief Executive
Officer and Chief Financial Officer have concluded that the Company&#146;s
disclosure controls and procedures (as defined in Rules&nbsp;13a-15(e) and 15d-15(e)
under the Securities Exchange Act of 1934, as amended) are effective.
</FONT>
<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There have been no significant changes in internal control over financial
reporting, for the period covered by this report, that have materially affected
or are reasonably likely to materially affect, the Company&#146;s internal control
over financial reporting.
</FONT>

<P align="center"><FONT size="2">23</FONT>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>
<!-- link1 "PART III" -->
<DIV align="left"><A NAME="013"></A></DIV>
<P align="center"><FONT size="2"><B>PART III</B>
</FONT>

<!-- link2 "Item&nbsp;10. Directors and Executive Officers of the Registrant" -->
<DIV align="left"><A NAME="014"></A></DIV>
<P align="left"><FONT size="2"><B>Item&nbsp;10. Directors and Executive Officers of the Registrant.</B>
</FONT>

<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The required information on directors and nominees is incorporated by
reference to pages 8 through 11 of the Company&#146;s Proxy Statement for the Annual
Meeting of Stockholders to be held April&nbsp;27, 2004. Information on executive
officers is set forth in Part I of this document on pages 20 through 22.
</FONT>
<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The required information on the audit committee financial expert is
incorporated by reference to page 13 (under the heading &#147;Financial Expert on
Audit Committee&#148;) of the Company&#146;s Proxy Statement for the Annual Meeting of
Stockholders to be held April&nbsp;27, 2004.
</FONT>
<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The required information on the identification of the audit committee is
incorporated by reference to pages 12 (under the caption &#147;Board Committees&#148;) to
13 of the Company&#146;s Proxy Statement for the Annual Meeting of Stockholders to
be held April&nbsp;27, 2004.
</FONT>
<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The required information on compliance with Section&nbsp;16(a) of the
Securities Exchange Act of 1934 is incorporated by reference to page 41 (under
the caption &#147;Section&nbsp;16(a) Beneficial Ownership Reporting Compliance&#148;) of the
Company&#146;s Proxy Statement for the Annual Meeting of Stockholders to be held
April&nbsp;27, 2004.
</FONT>
<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company has adopted a Code of Conduct &#150; <I>Our Values and Standards</I>
applicable to all employees, including the principal executive officer,
principal financial officer, and principal accounting officer. The Code of
Conduct is available on the Company&#146;s website at
<I>www.merck.com/about/corporategovernance</I> and in print to any
stockholder who requests it. The Company intends to post on this
website any amendments to, or waivers from, its Code of Conduct.
</FONT>
<!-- link2 "Item&nbsp;11. Executive Compensation" -->
<DIV align="left"><A NAME="015"></A></DIV>
<P align="left"><FONT size="2"><B>Item&nbsp;11. Executive Compensation.</B>
</FONT>

<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The information required for this item is incorporated by reference to
pages 16 (under the caption &#147;Compensation of Directors&#148;) to 17, 22 (under the
caption &#147;Compensation of the Chief Executive Officer&#148;), pages 23 to 25, 26
(beginning with the caption &#147;Annual Benefits Payable Under Merck &#038; Co., Inc.
Retirement Plans&#148;) to 29, and page 15 (under the caption &#147;Compensation
Committee Interlocks and Insider Participation&#148;) of the Company&#146;s Proxy
Statement for the Annual Meeting of Stockholders to be held April&nbsp;27, 2004.
</FONT>
<!-- link2 "Item&nbsp;12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters" -->
<DIV align="left"><A NAME="016"></A></DIV>
<P align="left"><FONT size="2"><B>Item&nbsp;12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</B>
</FONT>
<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Information with respect to securities authorized for issuance under
equity compensation plans is incorporated by reference to pages 25 (beginning
with the caption &#147;Equity Compensation Plan Information&#148;) to 26 of the Company&#146;s
Proxy Statement for the Annual Meeting of Stockholders to be held April&nbsp;27,
2004. Information with respect to security ownership of certain beneficial
owners and management is incorporated by reference to pages 18 (under the
caption &#147;Security Ownership of Certain Beneficial Owners and Management&#148;) to 19
of the Company&#146;s Proxy Statement for the Annual Meeting of Stockholders to be
held April&nbsp;27, 2004.
</FONT>
<!-- link2 "Item&nbsp;13. Certain Relationships and Related Transactions" -->
<DIV align="left"><A NAME="017"></A></DIV>
<P align="left"><FONT size="2"><B>Item&nbsp;13. Certain Relationships and Related Transactions.</B>
</FONT>

<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The information required for this item is incorporated by reference to
page 12 (under the caption &#147;Relationships with Outside Firms&#148;) and page 29
(under the caption &#147;Indebtedness of Management&#148;) of the Company&#146;s Proxy
Statement for the Annual Meeting of Stockholders to be held April&nbsp;27, 2004.
</FONT>
<!-- link2 "Item&nbsp;14. Principal Accountant Fees and Services" -->
<DIV align="left"><A NAME="018"></A></DIV>
<P align="left"><FONT size="2"><B>Item&nbsp;14. Principal Accountant Fees and Services.</B>
</FONT>

<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The information required for this item is incorporated by reference to
pages 31 (beginning with the caption &#147;Pre-Approval Policy for Services of
Independent Auditors&#148;) to 32 of the Company&#146;s Proxy Statement for the Annual
Meeting of Stockholders to be held April&nbsp;27, 2004.
</FONT>

<P align="center"><FONT size="2">24</FONT>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<!-- link1 "PART IV" -->
<DIV align="left"><A NAME="019"></A></DIV>
<P align="center"><FONT size="2"><B>PART IV</B>
</FONT>

<!-- link2 "Item&nbsp;15. Exhibits, Financial Statement Schedules, and Reports on Form&nbsp;8-K" -->
<DIV align="left"><A NAME="020"></A></DIV>
<P align="left"><FONT size="2"><B>Item&nbsp;15. Exhibits, Financial Statement Schedules, and Reports on Form&nbsp;8-K.</B>
</FONT>

<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;Documents filed as part of this Form&nbsp;10-K</B></FONT>

<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">
<TR valign="top">
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="1%" align="left" nowrap><FONT size="2"><B>1.</B></FONT></TD>
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="93%"><FONT size="2"><B>Financial Statements</B></FONT></TD>
</TR>
<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="1%" align="left" nowrap><FONT size="2">&nbsp;</FONT></TD>
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="93%"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;The following consolidated financial statements and report of independent
auditors are
incorporated herein by reference to the Company&#146;s 2003 Annual Report
to stockholders, as noted on page 23 of this document:</FONT></TD>
</TR>
<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="1%" align="left" nowrap><FONT size="2">&nbsp;</FONT></TD>
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="93%"><FONT size="2">Consolidated statement of income for the years ended December&nbsp;31,
2003, 2002 and 2001</FONT></TD>
</TR>
<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="1%" align="left" nowrap><FONT size="2">&nbsp;</FONT></TD>
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="93%"><FONT size="2">Consolidated statement of retained earnings for the years ended
December&nbsp;31, 2003, 2002 and 2001</FONT></TD>
</TR>
<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="1%" align="left" nowrap><FONT size="2">&nbsp;</FONT></TD>
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="93%"><FONT size="2">Consolidated statement of comprehensive income for the years ended
December&nbsp;31, 2003, 2002 and 2001</FONT></TD>
</TR>
<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="1%" align="left" nowrap><FONT size="2">&nbsp;</FONT></TD>
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="93%"><FONT size="2">Consolidated balance sheet as of December&nbsp;31, 2003 and 2002</FONT></TD>
</TR>
<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="1%" align="left" nowrap><FONT size="2">&nbsp;</FONT></TD>
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="93%"><FONT size="2">Consolidated statement of cash flows for the years ended December&nbsp;31,
2003, 2002 and 2001</FONT></TD>
</TR>
<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="1%" align="left" nowrap><FONT size="2">&nbsp;</FONT></TD>
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="93%"><FONT size="2">Notes to consolidated financial statements</FONT></TD>
</TR>
<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="1%" align="left" nowrap><FONT size="2">&nbsp;</FONT></TD>
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="93%"><FONT size="2">Report of PricewaterhouseCoopers LLP, independent auditors</FONT></TD>
</TR>
<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="1%" align="left" nowrap><FONT size="2"><B>2.</B></FONT></TD>
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="93%"><FONT size="2"><B>Financial Statement Schedules</B></FONT></TD>
</TR>
<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="1%" align="left" nowrap><FONT size="2">&nbsp;</FONT></TD>
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="93%"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;Schedules are omitted because they are either not required or not
applicable.</FONT></TD>
</TR>
</TABLE>
<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;Financial statements of affiliates carried on the equity basis have been
omitted because, considered individually or in the aggregate, such affiliates
do not constitute a significant subsidiary.
</FONT>
<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">
<TR valign="top">
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="1%" align="left" nowrap><FONT size="2"><B>3.</B></FONT></TD>
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="93%"><FONT size="2"><B>Exhibits</B></FONT></TD>
</TR>
</TABLE>

<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%">
<TR valign="bottom">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="84%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" nowrap align="center"><FONT size="1"><B>Exhibit</B></FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" nowrap align="center"><FONT size="1"><B>Number</B></FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD nowrap align="center"><FONT size="1"><B>Description</B></FONT></TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" nowrap align="center"><HR size="1" noshade></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD nowrap align="center"><HR size="1" noshade></TD>
</TR>
<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">2.1</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
&#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">Master Restructuring Agreement dated as of June&nbsp;19, 1998 between Astra AB, Merck &amp;
Co., Inc., Astra Merck Inc., Astra USA, Inc., KB USA, L.P., Astra Merck Enterprises,
Inc., KBI Sub Inc., Merck Holdings, Inc. and Astra Pharmaceuticals, L.P. (Portions of
this Exhibit are subject to a request for confidential treatment filed with the Commission)
&#151; Incorporated by reference to Form&nbsp;10-Q Quarterly Report for the period ended June&nbsp;30, 1998</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">3.1</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
&#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">Restated Certificate
of Incorporation of Merck &#038; Co., Inc. (September&nbsp;1, 2000)
&#151; Incorporated by reference to Form&nbsp;10-Q Quarterly Report for the period ended
September&nbsp;30, 2000</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">3.2</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
&#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">By-Laws of Merck
&#038; Co., Inc. (as amended effective February&nbsp;25, 1997) &#151; Incorporated by reference to Form&nbsp;10-Q Quarterly Report for the period ended
March&nbsp;31, 1997</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">*10.1</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
&#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">Executive Incentive Plan (as amended effective February&nbsp;27, 1996) &#151; Incorporated by
reference to Form&nbsp;10-K Annual Report for the fiscal year ended December&nbsp;31, 1995</FONT></TD>
</TR>


</TABLE>
</CENTER>



<P>
<HR size="1" width="18%" align="left" noshade>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">
<TR valign="top">
    <TD width="1%" align="left" nowrap><FONT size="2">*</FONT></TD>
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="96%"><FONT size="2">Management contract or compensatory plan or arrangement.</FONT></TD>
</TR>
</TABLE>

<P align="center"><FONT size="2">25</FONT>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>




<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%">
<TR valign="bottom">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="84%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" nowrap align="center"><FONT size="1"><B>Exhibit</B></FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" nowrap align="center"><FONT size="1"><B>Number</B></FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD nowrap align="center"><FONT size="1"><B>Description</B></FONT></TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" nowrap align="center"><HR size="1" noshade></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD nowrap align="center"><HR size="1" noshade></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">*10.2</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
&#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">Base Salary Deferral Plan (as adopted on October&nbsp;22, 1996, effective January&nbsp;1, 1997)
&#151; Incorporated by reference to Form&nbsp;10-K Annual Report for the fiscal year ended
December&nbsp;31, 1996</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">*10.3</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
&#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">Merck &#038; Co., Inc. Deferral Program (amended and restated November&nbsp;19, 2003)</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">*10.4</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
&#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">1991 Incentive Stock Plan (as amended effective February&nbsp;23, 1994) &#151; Incorporated by
reference to Form&nbsp;10-K Annual Report for the fiscal year ended December&nbsp;31, 1994</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">*10.5</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
&#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">1996 Incentive Stock Plan (as amended November&nbsp;24, 1998) &#151; Incorporated by
reference to Form&nbsp;10-Q Quarterly Report for the period ended June&nbsp;30, 1999</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">*10.6</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
&#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">2001 Incentive Stock Plan (amended and restated July&nbsp;22, 2003) &#151; Incorporated
by reference to Form&nbsp;10-Q Quarterly Report for the period ended September&nbsp;30, 2003</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">*10.7</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
&#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">2004 Incentive Stock Plan (amended July&nbsp;22, 2003) &#151; Incorporated by reference to
Registration Statement on Form&nbsp;S-8 (No.&nbsp;333-109296)</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">*10.8</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
&#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">Non-Employee Directors Stock Option Plan (as amended and restated
February&nbsp;24, 1998) &#151; Incorporated by reference to Form&nbsp;10-K Annual Report for the
fiscal year ended December&nbsp;31, 1997</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">*10.9</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
&#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">1996 Non-Employee
Directors Stock Option Plan (as amended April&nbsp;27, 1999) &#151; Incorporated by reference to Form&nbsp;10-Q Quarterly Report for the period ended
June&nbsp;30, 1999</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">*10.10</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
&#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">2001 Non-Employee
Directors Stock Option Plan (as amended April&nbsp;19, 2002) &#151; Incorporated by reference to Form&nbsp;10-Q Quarterly Report for the period ended
June&nbsp;30, 2002</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">*10.11</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
&#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">Supplemental Retirement Plan (as amended effective January&nbsp;1, 1995) &#151; Incorporated
by reference to Form&nbsp;10-K Annual Report for the fiscal year ended December&nbsp;31, 1994</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">*10.12</FONT></TD>    <TD><FONT size="2">&nbsp;</FONT></TD>    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
&#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">Retirement Plan for the Directors of Merck &#038; Co., Inc. (amended and restated
June&nbsp;21, 1996) &#151; Incorporated by reference to Form&nbsp;10-Q Quarterly Report for the
period ended June&nbsp;30, 1996</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">*10.13</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
&#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">Plan for Deferred Payment of Directors&#146; Compensation (amended and restated
November&nbsp;19, 2003)</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">10.14</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
&#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">Limited Liability Company Agreement of Merck Capital Ventures, LLC (Dated as of
November&nbsp;27, 2000) &#151; Incorporated by reference to Form&nbsp;10-K Annual Report for the
fiscal year ended December&nbsp;31, 2000</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">*10.15</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
&#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">Offer Letter between Merck &#038; Co., Inc. and Peter S. Kim, dated December&nbsp;15, 2000</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">10.16</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
&#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">Amended and Restated License and Option Agreement dated as of July&nbsp;1, 1998 between
Astra AB and Astra Merck Inc. &#151; Incorporated by reference to Form&nbsp;10-Q Quarterly
Report for the period ended June&nbsp;30, 1998</FONT></TD>
</TR>

</TABLE>
</CENTER>
<P>
<HR size="1" width="18%" align="left" noshade>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">
<TR valign="top">
    <TD width="1%" align="left" nowrap><FONT size="2">*</FONT></TD>
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="96%"><FONT size="2">Management contract or compensatory plan or arrangement.</FONT></TD>
</TR>
</TABLE>
<P align="center"><FONT size="2">26</FONT>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>




<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%">
<TR valign="bottom">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="84%">&nbsp;</TD>
</TR>
<TR valign="bottom">

    <TD colspan="3" nowrap align="center"><FONT size="1"><B>Exhibit</B></FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" nowrap align="center"><FONT size="1"><B>Number</B></FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD nowrap align="center"><FONT size="1"><B>Description</B></FONT></TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" nowrap align="center"><HR size="1" noshade></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD nowrap align="center"><HR size="1" noshade></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">10.17</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
&#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">KBI Shares Option Agreement dated as of July&nbsp;1, 1998 by and among Astra AB, Merck
&#038; Co., Inc. and Merck Holdings, Inc. &#151; Incorporated by reference to Form&nbsp;10-Q
Quarterly Report for the period ended June&nbsp;30, 1998</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">10.18</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
&#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">KBI-E Asset Option Agreement dated as of July&nbsp;1, 1998 by and among Astra AB, Merck
&#038; Co., Inc., Astra Merck Inc. and Astra Merck Enterprises Inc. &#151; Incorporated by
reference to Form&nbsp;10-Q Quarterly Report for the period ended June&nbsp;30, 1998</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">10.19</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
&#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">KBI Supply Agreement dated as of July&nbsp;1, 1998 between Astra Merck Inc. and Astra
Pharmaceuticals, L.P. (Portions of this Exhibit are subject to a request for confidential
treatment filed with the Commission) &#151; Incorporated by reference to Form&nbsp;10-Q
Quarterly Report for the period ended June&nbsp;30, 1998</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">10.20</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
&#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">Second Amended and Restated Manufacturing Agreement dated as of July&nbsp;1, 1998
among Merck &#038; Co., Inc., Astra AB, Astra Merck Inc. and Astra
USA, Inc. &#151;
Incorporated by reference to Form&nbsp;10-Q Quarterly Report for the period ended
June&nbsp;30, 1998</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">10.21</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
&#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">Limited Partnership Agreement dated as of July&nbsp;1, 1998 between KB USA, L.P. and KBI
Sub Inc. &#151; Incorporated by reference to Form&nbsp;10-Q Quarterly Report for the period
ended June&nbsp;30, 1998</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">10.22</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
&#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">Distribution Agreement dated as of July&nbsp;1, 1998 between Astra Merck Enterprises Inc.
and Astra Pharmaceuticals, L.P. &#151; Incorporated by reference to Form&nbsp;10-Q Quarterly
Report for the period ended June&nbsp;30, 1998</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">10.23</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
&#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">Agreement to Incorporate Defined Terms dated as of June&nbsp;19, 1998 between Astra AB,
Merck &#038; Co., Inc., Astra Merck Inc., Astra USA, Inc., KB USA, L.P., Astra Merck
Enterprises Inc., KBI Sub Inc., Merck Holdings, Inc. and Astra
Pharmaceuticals, L.P. &#151; Incorporated by reference to Form&nbsp;10-Q Quarterly Report for the period ended
June&nbsp;30, 1998</FONT></TD>
</TR>
<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">12</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&#151;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">Computation of Ratios of Earnings to Fixed Charges</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">13</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
&#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">2003 Annual Report to stockholders (only those portions incorporated by reference in
this document are deemed &#147;filed&#148;)</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">14</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
&#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">Code of Conduct &#150; <I>Our Values and Standards</I></FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">21</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
&#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">List of subsidiaries</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">23</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
&#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">Consent of
Independent Accountants &#151; Contained on page 30 of this Report</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>


<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">24.1</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
&#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">Power of Attorney</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">24.2</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
&#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">Certified Resolution of Board of Directors</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">31.1</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
&#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">Rule&nbsp;13a &#150; 14(a)/15d-14(a) Certification of Chief Executive Officer</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">31.2</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
&#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">Rule&nbsp;13a &#150; 14(a)/15d-14(a) Certification of Chief Financial Officer</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">32.1</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
&#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">Section&nbsp;1350 Certification of Chief Executive Officer</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD valign="top" align="right"><FONT size="2">32.2</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
&#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">Section&nbsp;1350 Certification of Chief Financial Officer</FONT></TD>
</TR>
</TABLE>
</Center>



<P align="center"><FONT size="2">27</FONT>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>
<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None of the instruments defining the rights of holders of long-term debt
of the Company and its subsidiaries (Exhibit&nbsp;Number 4) are being filed since
the total amount of securities authorized under any of such instruments taken
individually does not exceed 10% of the total assets of the Company and its
subsidiaries on a consolidated basis. The Company agrees to furnish a copy of
such instruments to the Commission upon request.
</FONT>
<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Copies of the exhibits may be obtained by stockholders upon written
request directed to the Stockholder Services Department, Merck &#038; Co., Inc.,
P.O. Box 100&#151;WS 3AB-40, Whitehouse Station, New Jersey 08889-0100 accompanied
by check in the amount of $5.00 payable to Merck &#038; Co., Inc. to cover
processing and mailing costs.
</FONT>
<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;Reports on Form&nbsp;8-K</B>
</FONT>

<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">
<TR valign="top">
    <TD width="1%" align="left" nowrap><FONT size="2">&nbsp;</FONT></TD>
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="96%"><FONT size="2">During the three-month period ended December&nbsp;31, 2003, the Company
furnished:</FONT></TD>
</TR>
</TABLE>
<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">
<TR valign="top">
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="1%" align="left" nowrap><FONT size="2">(1)</FONT></TD>
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="93%"><FONT size="2">one Current Report on Form&nbsp;8-K under Item&nbsp;9 &#151; Regulation&nbsp;FD
Disclosure and Item&nbsp;12 &#151;  Results of Operations and Financial
Condition: Report dated and furnished October&nbsp;22, 2003, regarding
earnings for third quarter 2003 and certain supplemental
information; and</FONT></TD>
</TR>
<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="1%" align="left" nowrap><FONT size="2">(2)</FONT></TD>
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="93%"><FONT size="2">three Current Reports on Form&nbsp;8-K under Item&nbsp;9 &#151;
Regulation&nbsp;FD Disclosure:</FONT></TD>
</TR>
<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>
</table>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR valign="top">
    <TD width="7%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="1%" align="left" nowrap><FONT size="2">(i)</FONT></TD>
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="89%"><FONT size="2">Report dated and furnished December&nbsp;3, 2003,
regarding financial guidance for 2004.</FONT></TD>
</TR>
<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="1%" align="left" nowrap><FONT size="2">(ii)</FONT></TD>
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="93%"><FONT size="2">Report dated and furnished December&nbsp;9, 2003, regarding annual business briefing
presentations.</FONT></TD>
</TR>
<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="1%" align="left" nowrap><FONT size="2">(iii)</FONT></TD>
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="93%"><FONT size="2">Report dated and furnished December&nbsp;9, 2003, regarding the Company&#146;s annual business
briefing to analysts.</FONT></TD>
</TR>
</TABLE>

<P align="center"><FONT size="2">28</FONT>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>




<!-- link1 "SIGNATURES" -->
<DIV align="left"><A NAME="021"></A></DIV>
<P align="center"><FONT size="2"><B>SIGNATURES</B>
</FONT>

<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;<B>Pursuant to the requirements of Section&nbsp;13 or 15(d) of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.</B>
</FONT>
<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%">
<TR valign="bottom">
    <TD width="40%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD colspan="5" valign="top" align="left"><FONT size="2">MERCK &#038; CO., INC.</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">Dated: March&nbsp;10, 2004</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD colspan="3" valign="top" align="left"><FONT size="2">By RAYMOND V. GILMARTIN</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD colspan="3" valign="top" align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;(Chairman of the Board,</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD colspan="3" valign="top" align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;President and Chief Executive Officer)</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">By CELIA A. COLBERT</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;&nbsp;&nbsp;Celia A. Colbert</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;&nbsp;&nbsp;(Attorney-in-Fact)</FONT></TD>
</TR>
</TABLE>
</CENTER>
<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;<B>Pursuant to the requirements of the Securities Exchange Act of 1934, this
report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.</B>
</FONT>
<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%">
<TR valign="bottom">
    <TD width="29%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="48%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="13%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD nowrap align="center"><FONT size="1"><B>Signatures</B></FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD nowrap align="center"><FONT size="1"><B>Title</B></FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD nowrap align="center"><FONT size="1"><B>Date</B></FONT></TD>
</TR>
<TR valign="bottom">
    <TD nowrap align="center"><HR size="1" noshade></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD nowrap align="center"><HR size="1" noshade></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD nowrap align="center"><HR size="1" noshade></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><FONT size="2">RAYMOND V. GILMARTIN</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
Chairman of the Board,
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">March&nbsp;10, 2004</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
&nbsp;&nbsp;&nbsp;&nbsp;President and Chief Executive</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
&nbsp;&nbsp;&nbsp;&nbsp;Officer; Principal Executive</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
&nbsp;&nbsp;&nbsp;&nbsp;Officer; Director</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">JUDY C. LEWENT</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
Executive Vice President, Chief
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">March&nbsp;10, 2004</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
&nbsp;&nbsp;&nbsp;&nbsp;Financial Officer and President, Human</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
&nbsp;&nbsp;&nbsp;&nbsp;Health Asia; Principal Financial Officer</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">RICHARD C. HENRIQUES JR</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
Vice President, Controller;
Principal Accounting Officer
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">March&nbsp;10, 2004</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">LAWRENCE A. BOSSIDY</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
Director
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">March&nbsp;10, 2004</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">WILLIAM G. BOWEN</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
Director
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">March&nbsp;10, 2004</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">JOHNNETTA B. COLE</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
Director
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">March&nbsp;10, 2004</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">WILLIAM M. DALEY</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
Director
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">March&nbsp;10, 2004</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">WILLIAM B. HARRISON JR</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
Director
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">March&nbsp;10, 2004</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">WILLIAM N. KELLEY</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
Director
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">March&nbsp;10, 2004</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">HEIDI G. MILLER</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
Director
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">March&nbsp;10, 2004</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">THOMAS E. SHENK</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
Director
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">March&nbsp;10, 2004</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">SAMUEL O. THIER</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
Director
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">March&nbsp;10, 2004</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">WENDELL P. WEEKS</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
Director
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">March&nbsp;10, 2004</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">PETER C. WENDELL</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
Director
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">March&nbsp;10, 2004</FONT></TD>
</TR>
</TABLE>
</CENTER>
<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;<B>Celia A. Colbert, by signing her name hereto, does hereby sign this
document pursuant to powers of attorney duly executed by the persons named,
filed with the Securities and Exchange Commission as an exhibit to this
document, on behalf of such persons, all in the capacities and on the date
stated, such persons including a majority of the directors of the Company.</B>
</FONT>
<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%">
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="50%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
By CELIA A. COLBERT</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
&nbsp;&nbsp;&nbsp;Celia A. Colbert</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
&nbsp;&nbsp;&nbsp;(Attorney-in-Fact)</FONT></TD>
</TR>
</TABLE>
</CENTER>
<P align="center"><FONT size="2">29</FONT>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<P align="right"><FONT size="2"><B>Exhibit&nbsp;23</B></FONT>

<P align="center"><FONT size="2"><B>CONSENT OF INDEPENDENT ACCOUNTANTS</B>
</FONT>

<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We hereby consent to the incorporation by reference in the Registration
Statements on Form&nbsp;S-3 (Nos. 33-39349, 33-60322, 33-51785, 33-57421, 333-17045,
333-36383, 333-77569, 333-72546 and 333-87034) and on Form&nbsp;S-8 (Nos. 33-21087,
33-21088, 33-40177, 33-51235, 33-53463, 33-64273, 33-64665, 333-91769,
333-30526, 333-31762, 333-40282, 333-53246, 333-56696, 333-72206, 333-65796,
333-101519 and 333-109296) of Merck &#038; Co., Inc. of our report dated February
20, 2004, relating to the consolidated financial statements, which appears in
the Annual Report to stockholders, which is incorporated in this Annual Report
on Form&nbsp;10-K.
</FONT>
<P align="left"><FONT size="2">PricewaterhouseCoopers LLP
</FONT>

<P align="left"><FONT size="2">Florham Park, New Jersey<BR>
March&nbsp;10, 2004</FONT>


<P align="center"><FONT size="2">30</FONT>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<P align="center"><FONT size="2"><B>EXHIBIT INDEX</B>
</FONT>

<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="85%">
<TR valign="bottom">
    <TD valign="top" align="center">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="84%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="1"><B>Exhibit</B></FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
</TR>
<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="1"><B>Number</B></FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD nowrap align="center"><FONT size="1"><B>Description</B></FONT></TD>
</TR>
<TR valign="bottom">
    <TD valign="top" align="center"><HR size="1" noshade></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD nowrap align="center"><HR size="1" noshade></TD>
</TR>
<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">&nbsp;&nbsp;&nbsp;2.1</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2"> &#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">Master Restructuring
Agreement dated as of June&nbsp;19, 1998 between Astra AB, Merck &amp;
Co., Inc., Astra Merck Inc., Astra USA, Inc., KB USA, L.P., Astra Merck Enterprises,
Inc., KBI Sub Inc., Merck Holdings, Inc. and Astra Pharmaceuticals, L.P. (Portions of
this Exhibit are subject to a request for confidential treatment filed with the Commission)
&#151; Incorporated by reference to Form&nbsp;10-Q Quarterly Report for the period ended
June&nbsp;30, 1998</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">&nbsp;&nbsp;&nbsp;3.1</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2"> &#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">Restated Certificate
of Incorporation of Merck &#038; Co., Inc. (September&nbsp;1, 2000) &#151; Incorporated
by reference to Form&nbsp;10-Q Quarterly Report for the period ended
September&nbsp;30, 2000</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>
<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">&nbsp;&nbsp;&nbsp;3.2</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2"> &#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">By-Laws of Merck &#038; Co., Inc. (as amended effective February&nbsp;25, 1997) &#151;
Incorporated by reference to Form&nbsp;10-Q Quarterly Report for the period ended
March&nbsp;31, 1997</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">*10.1</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2"> &#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">Executive Incentive Plan (as amended effective February&nbsp;27, 1996) &#151; Incorporated by
reference to Form&nbsp;10-K Annual Report for the fiscal year ended December&nbsp;31, 1995</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">*10.2</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2"> &#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">Base Salary Deferral Plan (as adopted on October&nbsp;22, 1996, effective January&nbsp;1, 1997)
&#151; Incorporated by reference to Form&nbsp;10-K Annual Report for the fiscal year ended
December&nbsp;31, 1996</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">*10.3</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2"> &#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">Merck &#038; Co., Inc. Deferral Program (amended and restated November&nbsp;19, 2003)</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">*10.4</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2"> &#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">1991 Incentive Stock Plan (as amended effective February&nbsp;23, 1994) &#151; Incorporated by
reference to Form&nbsp;10-K Annual Report for the fiscal year ended December&nbsp;31, 1994</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">*10.5</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2"> &#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">1996 Incentive Stock Plan (as amended November&nbsp;24, 1998) &#151; Incorporated by
reference to Form&nbsp;10-Q Quarterly Report for the period ended June&nbsp;30, 1999</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">*10.6</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2"> &#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">2001 Incentive Stock Plan (amended and restated July&nbsp;22, 2003) &#151; Incorporated
by reference to Form&nbsp;10-Q Quarterly Report for the period ended September&nbsp;30, 2003</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">*10.7</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2"> &#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">2004 Incentive Stock Plan (amended July&nbsp;22, 2003) &#151; Incorporated by reference to
Registration Statement on Form&nbsp;S-8 (No.&nbsp;333-109296)</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">*10.8</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2"> &#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">Non-Employee Directors Stock Option Plan (as amended and restated
February&nbsp;24, 1998) &#151; Incorporated by reference to Form&nbsp;10-K Annual Report for the
fiscal year ended December&nbsp;31, 1997</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">*10.9</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2"> &#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">1996 Non-Employee Directors Stock Option Plan (as amended April&nbsp;27, 1999) &#151;
Incorporated by reference to Form&nbsp;10-Q Quarterly Report for the period ended
June&nbsp;30, 1999</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">*10.10&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2"> &#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">2001 Non-Employee Directors Stock Option Plan (as amended April&nbsp;19, 2002) &#151;
Incorporated by reference to Form&nbsp;10-Q Quarterly Report for the period ended
June&nbsp;30, 2002</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">*10.11&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2"> &#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">Supplemental Retirement Plan (as amended effective January&nbsp;1, 1995) &#151; Incorporated
by reference to Form&nbsp;10-K Annual Report for the fiscal year ended December&nbsp;31, 1994</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>
</TABLE>
</CENTER>
<P>
<HR size="1" width="18%" align="left" noshade>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">
<TR valign="top">
    <TD width="1%" align="left" nowrap><FONT size="2">*</FONT></TD>
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="96%"><FONT size="2">Management contract or compensatory plan or arrangement.</FONT></TD>
</TR>
</TABLE>
<P align="center"><FONT size="2">1</FONT>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>




<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="85%">
<TR valign="bottom">
    <TD valign="top" align="center">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="84%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="1"><B>Exhibit</B></FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
</TR>
<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="1"><B>Number</B></FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD nowrap align="center"><FONT size="1"><B>Description</B></FONT></TD>
</TR>
<TR valign="bottom">
    <TD valign="top" align="center"><HR size="1" noshade></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD nowrap align="center"><HR size="1" noshade></TD>
</TR>
<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">*10.12</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2"> &#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">Retirement Plan for the Directors of Merck &#038; Co., Inc. (amended and restated
June&nbsp;21, 1996) &#151; Incorporated by reference to Form&nbsp;10-Q Quarterly Report for the
period ended June&nbsp;30, 1996</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">*10.13</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2"> &#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">Plan for Deferred Payment of Directors&#146; Compensation (amended and restated
November&nbsp;19, 2003)</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">10.14</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2"> &#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">Limited Liability Company Agreement of Merck Capital Ventures, LLC (Dated as of
November&nbsp;27, 2000) &#151; Incorporated by reference to Form&nbsp;10-K Annual Report for the
fiscal year ended December&nbsp;31, 2000</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">*10.15</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2"> &#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">Offer Letter between Merck &#038; Co., Inc. and Peter S. Kim, dated December&nbsp;15, 2000</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">10.16</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2"> &#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">Amended and Restated License and Option Agreement dated as of July&nbsp;1, 1998 between
Astra AB and Astra Merck Inc. &#151; Incorporated by reference to Form&nbsp;10-Q Quarterly
Report for the period ended June&nbsp;30, 1998</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">10.17</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2"> &#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">KBI Shares Option Agreement dated as of July&nbsp;1, 1998 by and among Astra AB, Merck
&#038; Co., Inc. and Merck Holdings, Inc. &#151; Incorporated by reference to Form&nbsp;10-Q
Quarterly Report for the period ended June&nbsp;30, 1998</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">10.18</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2"> &#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">KBI-E Asset Option Agreement dated as of July&nbsp;1, 1998 by and among Astra AB, Merck
&#038; Co., Inc., Astra Merck Inc. and Astra Merck Enterprises Inc. &#151; Incorporated by
reference to Form&nbsp;10-Q Quarterly Report for the period ended June&nbsp;30, 1998</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">10.19</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2"> &#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">KBI Supply Agreement dated as of July&nbsp;1, 1998 between Astra Merck Inc. and Astra
Pharmaceuticals, L.P. (Portions of this Exhibit are subject to a request for confidential
treatment filed with the Commission) &#151; Incorporated by reference to Form&nbsp;10-Q
Quarterly Report for the period ended June&nbsp;30, 1998</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">10.20</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2"> &#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">Second Amended and Restated Manufacturing Agreement dated as of July&nbsp;1, 1998
among Merck &#038; Co., Inc., Astra AB, Astra Merck Inc. and Astra
USA, Inc. &#151;
Incorporated by reference to Form&nbsp;10-Q Quarterly Report for the period ended
June&nbsp;30, 1998</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">10.21</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2"> &#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">Limited Partnership Agreement dated as of July&nbsp;1, 1998 between KB USA, L.P. and KBI
Sub Inc. &#151; Incorporated by reference to Form&nbsp;10-Q Quarterly Report for the period
ended June&nbsp;30, 1998</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">10.22</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2"> &#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">Distribution Agreement dated as of July&nbsp;1, 1998 between Astra Merck Enterprises Inc.
and Astra Pharmaceuticals, L.P. &#151; Incorporated by reference to Form&nbsp;10-Q Quarterly
Report for the period ended June&nbsp;30, 1998</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">10.23</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2"> &#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">Agreement to Incorporate Defined Terms dated as of June&nbsp;19, 1998 between Astra AB,
Merck &#038; Co., Inc., Astra Merck Inc., Astra USA, Inc., KB USA, L.P., Astra Merck
Enterprises Inc., KBI Sub Inc., Merck Holdings, Inc. and Astra
Pharmaceuticals, L.P. &#151;
Incorporated by reference to Form&nbsp;10-Q Quarterly Report for the period ended
June&nbsp;30, 1998</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">12</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2"> &#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">Computation of Ratios of Earnings to Fixed Charges
</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">13</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2"> &#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">2003 Annual Report to stockholders (only those portions incorporated by reference in
this document are deemed &#147;filed&#148;)</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">14</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2"> &#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">Code of Conduct - <I>Our Values and Standards</I></FONT></TD>
</TR>
</TABLE>
</CENTER>
<P>
<HR size="1" width="18%" align="left" noshade>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">
<TR valign="top">
    <TD width="1%" align="left" nowrap><FONT size="2">*</FONT></TD>
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="96%"><FONT size="2">Management contract or compensatory plan or arrangement.</FONT></TD>
</TR>
</TABLE>
<P align="center"><FONT size="2">2</FONT>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>
<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="85%">
<TR valign="bottom">
    <TD valign="top" align="center">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="84%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="1"><B>Exhibit</B></FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
</TR>
<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="1"><B>Number</B></FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD nowrap align="center"><FONT size="1"><B>Description</B></FONT></TD>
</TR>
<TR valign="bottom">
    <TD valign="top" align="center"><HR size="1" noshade></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD nowrap align="center"><HR size="1" noshade></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">21</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2"> &#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">List of subsidiaries</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">23</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2"> &#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">Consent of
Independent Accountants &#151; Contained on page 30 of this Report</FONT></TD>
</TR>


<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">24.1</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2"> &#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">Power of Attorney</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">24.2</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2"> &#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">Certified Resolution of Board of Directors</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">31.1</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2"> &#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">Rule&nbsp;13a &#150; 14(a)/15d-14(a) Certification of Chief Executive Officer</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">31.2</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2"> &#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">Rule&nbsp;13a &#150; 14(a)/15d-14(a) Certification of Chief Financial Officer</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">32.1</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2"> &#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">Section&nbsp;1350 Certification of Chief Executive Officer</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><FONT size="2">32.2</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2"> &#151;
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">Section&nbsp;1350 Certification of Chief Financial Officer</FONT></TD>
</TR>


</TABLE>
</CENTER>
<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None of the instruments defining the rights of holders of long-term debt
of the Company and its subsidiaries (Exhibit&nbsp;Number 4) are being filed since
the total amount of securities authorized under any of such instruments taken
individually does not exceed 10% of the total assets of the Company and its
subsidiaries on a consolidated basis. The Company agrees to furnish a copy of
such instruments to the Commission upon request.
</FONT>
<P align="center"><FONT size="2">3</FONT>
</BODY>
</HTML>

</TEXT>
</DOCUMENT>
